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ABSTRACT 
 
Among the first diagnostic tests performed upon finding a tumor in the breast is 
the determination of the expression of three proteins: the Estrogen Receptor α (ERα), the 
Progesterone Receptor (PR) and Heregulin 2 (HER2).  The ER, though often considered 
responsible for driving tumor growth, is usually indicative of a good prognosis as ER-
positive tumors are typically more indolent in nature and responsive to endocrine therapy.   
Long after estrogens were known to drive the growth of many breast tumors, the estrogen 
receptor was identified.  The ER is a modular transcription factor known to regulate the 
expression of over a thousand genes in breast cancer cells.   
As a master regulator of transcription, ER can impact the transcription and 
subsequent expression of many proteins that ultimately determine the growth and 
invasiveness of a tumor.  As a transcriptional regulator, activation of ER with its cognate 
ligand, estradiol, results in a cascade of changes beginning with chromatin remodeling of 
estradiol-regulated genes.   
In an attempt to identify ER-interacting proteins that aid in this chromatin 
unfolding activity, we performed a yeast two-hybrid screen using amino acids 420-534 of 
ERα as bait and identified Eukaryotic translation initiation factor 3 subunit F (eIF3f) as 
an interaction partner.  Fluorescence microscopy suggests that in the presence of 
estradiol, the location of ERα-eIF3f changes.  Though unclear if eIF3f, a translation 
factor, plays a role in chromatin unfolding, as a translation factor, we suggest that the 
interaction between eIF3f and ERα establishes a link through which estradiol can regulate 
translation.  In support of this link, we find ERα in polysome profile fractions. 
Knockdown of eIF3f also appears to change the solubility of ERα within the nucleus.  
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eIF3f knockdown also results in changes in steady-state mRNA levels of specific 
estradiol-target genes. Upon isolation of mRNA following polysome fractionation, we 
observe differences in the rate of translation of several estradiol-regulated mRNAs.  
Unlike other ERα-interacting partners such as Jab1 and E6-AP, eIF3f interacts with a 
shorter form of ERα.   
The effects of estradiol on cellular function are pleiotropic.  As a transcriptional 
regulator, ER regulates many genes that can have a subsequent impact on other cellular 
functions.  These so-called secondary effects are often associated as the principle actions 
of estradiol.   We identify leucine-rich repeats and immunoglobulin-like domains protein 
1 (LRIG1) as an estradiol-regulated gene.  LRIG1 is a negative regulator of Receptor 
Tyrosine Kinase (RTK) signaling.  Up-regulation of LRIG1 mRNA and protein is 
mediated by the estrogen receptor-α (ERα) and we identified the regions of the LRIG1 
gene to which ER binds. LRIG1 regulation by estradiol helps to explain how tumors 
typically utilize either estradiol or growth factor pathways, but rarely both, as mitogenic 
stimuli.  Increased LRIG1, in response to estradiol, results in decreased signaling through 
RTK pathways.  The impact of LRIG1 regulation by estradiol is cell-type specific.  
LRIG1 protein levels are important for both the growth of cells as well as colony 
formation and invasiveness of ERα-positive and HER2-positive BT-474 and ERα-
positive and HER2-negative MCF-7 breast cancer cell lines.  LRIG1 regulation by 
estradiol may be important for breast cancer etiology and phenotypic properties by 
influencing signaling pathways such as the AKT and MAPK pathways, which help to 
determine the breast tumor subtype as well as responsiveness to cancer treatments.  
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CHAPTER 1 
INTRODUCTION AND SIGNIFICANCE 
 
Role of Estrogens and the Estrogen Receptor 
Estrogens are well know for their role in reproductive function including 
mammary gland development, ovarian follicular growth and female fertility, but also 
play critical roles in other physiological processes including the maintenance of bone 
mineral density, cardiovascular function and brain development and memory (1).  
Apart from their role in the normal physiology, Estrogens are also known to play a 
significant role in the pathophysiology of breast cancer.  Even before the identification 
of the Estrogen Receptor it was known that removal of the ovaries, the primary source 
of estrogen in women, could prevent the growth of most breast tumors.   As such, 
removal of the ovaries was the first effective treatment for breast tumors.  With the 
identification of an estrogen-binding protein in the labs of Elwood Jensen (2) and Jack 
Gorski (3) in the late 1950’s and early 1960’s and subsequent cloning of the receptor in 
1986 (4), we are able to better understand some of the molecular underpinnings 
responsible for the observed pleiotropic effects of estrogen.  Salient to these 
underpinnings is the way in which ER modulates the transcription of hundreds of genes 
in several different target tissues.  This understanding has coincided with the 
development of much less invasive breast cancer therapies including the drugs 
Tamoxifen and more recently the aromatase inhibitors Letrozole and Anastrozole.  
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Classical Mechanisms of Estrogen Action 
The Estrogen Receptor is a member of the nuclear receptor superfamily of 48 
phylogenetically related proteins that include such notables as Androgen Receptor 
(AR), Progesterone Receptor (PR), Gonadotropin Receptor (GR) and the ERα isoform, 
Estrogen Receptor β (ERβ) (5).   Nuclear hormone receptors function as ligand-
activated transcription factors, utilizing a signaling molecule (i.e. 17β-estradiol) to 
activate transcription of their cognate target genes.  As typical of nuclear hormone 
receptors, ER contains several modular domains to which specific functions can be 
ascribed.  ER contains two transcription-activation of function (AF) domains known as 
AF-1 and AF-2.  The amino-terminal A/B domain contains a constitutive ligand 
independent AF1 domain (6) while the E domain contains the ligand-binding domain 
(LBD), largely responsible for the observed AF-2 properties.  Upon binding of ligand 
to the LBD, the AF1 domain interacts with the AF-2 domain.  This interaction is 
enabled by the flexible D domain or hinge region and is required for maximal 
transcriptional activation.  The interaction between the two AF domains helps to hold 
the receptor in a conformation that exposes the C domain, containing the DNA-binding 
domain (DBD). The DBD consists of two non-equivalent zinc-finger binding motifs 
responsible for determining the target-sequence specificity of ER (7-9).   The amino-
terminal zinc-finger recognizes and directly binds to the ERE, while the carboxy-
terminal zinc finger stabilizes the ER bound to the DNA through the phosphate 
backbone of the DNA double helix (10).  
Upon ligand binding, another important conformational change occurs in the 
LBD of the ER that helps to facilitate transcriptional modulation by ER.  The LBD is 
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composed of several α-helices that together form a hydrophobic cleft.  In particular, 
the position of helix 12, relative to helices 3,4 and 5, changes dramatically upon ligand 
binding (11, 12).  Ligand binding causes the repositioning of helix 12 in a way that 
exposes the hydrophobic cleft of helices 3,4 and 5, thereby allowing for the binding of 
coactivator proteins via an LxxLL motif, also known as a nuclear receptor box, (NR 
box) (13, 14).  Many coactivator proteins contain LxxLL motifs where L is leucine and 
x can be any amino acid.  The first family of proteins identified as capable of binding 
ERα was the SRC/p160 family (15).   SRC-1, SRC-2 (GRIP-1/TIF-2) and SRC-3 
(ACTR/AIB1) all bind to the hydrophobic cleft of ER via their LxxLL motif (13, 14, 
16, 17).  The important role for these proteins in ER biology is highlighted by the fact 
that SRC-3, also known as amplified in breast cancer 1 (AIB1), is, as it’s name 
suggests, amplified in many estrogen-dependent tumors (18, 19). 
 ER has been reported to recruit over a hundred different cofactors that can 
modify transcriptional output (20, 21).  Most of these cofactors function through one of 
three main mechanisms: 1) histone modification, 2) DNA modification or 3) ATP-
dependent chromatin modification or they help to recruit proteins that perform one or 
more of these three functions..  Two of the three aforementioned SRC/p160 family 
members have intrinsic histone acetyl transferase (HAT) activity (SRC-1 and SRC-3) 
that masks the positive charge on the lysine residues of histone proteins, thereby 
decreasing their affinity for negatively charged DNA (22, 23). SRC/p160 proteins also 
help to recruitment other coactivators such as p300/CBP proteins that also posses HAT 
activity (24).  Coactivator-associated arginine methyltransferase 1 (25) is another ER-
coactivator that enhances transcription by methylating histone H3 (24-28).  
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In addition to the SRC/p160 and p300/CBP coactivators, ER is known to recruit 
ATP-dependent chromatin remodeling factors.  In particular, the SWI/SNF complex is 
required for transcriptional activation by ER.  Recruitment of the SWI/SNF complex to 
activated ER can be mediated through the protein BAF57 (29).  As with many ER 
coactivators, BAF57 also interacts with members of the SRC/p160 family.  
 
Chromatin remodeling  
While ER is known to have over a hundred binding partners that modulate the 
transcriptional regulation of estrogen-target genes, our understanding of the 
contribution of these many coregulators is the result of investigation of transcriptional 
regulation of individual genes.  With the application of micro array technology, the 
ability to observe the impact of estrogens on steady-state mRNA level as well as ER 
occupancy is now possible.  Furthermore, the contributions of various coregulators to 
the differential regulation of estrogen target-genes and ER occupancy can now be 
observed on a gene-by-gene basis through the use of chromatin-immunoprecipitation 
followed by micro-array experiments, or so called ChIP on chip experiments (30-35). 
 
Rapid actions of estrogens 
 In addition to the nuclear actions of ER, it has becoming increasingly clear that 
the full effects of estrogens upon cellular function also include events initiated by the 
receptor outside the nucleus.  These events include activation of several pathways such 
as the JUN NH2-terminal kinase (Jnk), p38, phosphatidylinositol 3-kinase (PI3K or 
AKT) and mitogen-activated protein kinases (MAPK) signaling pathways, and 
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typically occur at or near the cell membrane (36, 37).  Initiation of these cascade 
pathways can be very rapid and are consistent with one of the early observations of 
hormone actions, namely that steroids such as estrogen can have effects on the cell that 
are too rapid to involve transcriptional regulation (38).   
 In principle, activation of the PI3K and MAPK pathways by estradiol is similar 
to activation of these pathways by growth factors such as epidermal growth factor 
(EGF) and Heregulin (HRG) in that the same downstream factors are often activated. 
PI3K, MAPK and estradiol can impact cell survival through multiple mechanisms.  In 
particular, anti-estrogens such as Tamoxifen impact many of the same cellular 
processes as do signaling through the PI3K and MAPK pathways.  This includes 
regulation and/or phosphorylation of the pro-apoptotic proteins BAD (39, 40), caspase-
9 (41, 42). Forkhead transcription factors are also known to be regulated by the PI3K 
and MAPK pathway and have been reported to impact gene expression of ER-
regulated genes (43).  The PI3K, MAPK and ER pathways also regulate the cell cycle 
at the G1-S transition, and anti-estrogen resistant tumors are known to demonstrate 
activation of mammalian target of rapamycin (mTOR) and the translational regulatory 
protein 4E-binding protein-1 (4E-BP1), similar to tumors containing increased MAPK 
and/or AKT signaling (44, 45).  There is also known cross-talk between the PI3K, 
MAPK pathways and estradiol signaling including the phosphorylation of ERα by 
activation of PI3K or MAPK (46-48).  EGF was even reported to aid in the estrogen 
response of growth and differentiation in mouse uterus and vagina (49).  But clearly 
growth factors such as EGF or HRG and estradiol affect cells differently as they are 
not functionally equivalent.  As such, there is considerable complexity and diversity in 
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the transcriptional outcome of activation of the PI3K and MAPK pathways and the ER 
pathway, depending on the cell type and proteome of the cell.  These differences in 
kinase pathway activation are suggested to be the result of several factors including the 
length and intensity of activation within these pathways (50).  
 Additional, complexity is found in the fact that activation of both the PI3K and 
MAPK pathway can result in phosphorylation of ER. Consensus target sites for these 
kinases have been functionally characterized within the N-terminal activation function-
1 (AF-1) domain of ERα and ERβ. Serines -104, -106 and -118 of ERα have been 
shown to be phosphorylated by MAPK (47, 48, 51).  Serine -167 has been described as 
a functional PI3K target site (46).   
 
Non-classical signaling through ER 
Binding of estradiol to the ER initiates a cascade of events that results in the 
transcriptional regulation of any number of genes.  In the absence of ligand, the ER 
predominantly resides in the nucleus of the cell, bound to heat-shock proteins such as 
Hsp90, preventing it from stably homo-dimerizing and interacting with DNA.  Upon 
ligand binding, ER undergoes conformational changes allowing for stable homo-
dimerization as well as greatly increasing it’s binding affinity for cognate target 
sequences, commonly referred to as estrogen-responsive elements (EREs).   
 
Interplay between ER and Her2/Growth factors 
Tumor growth is often driven by one of two signaling pathways: ligand-
activated ERα, or signaling through the receptor tyrosine (RTK) signaling pathway 
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(52).  RTK signaling is mediated through members of the Epidermal Growth Factor 
Receptor (EGFR) family.  This includes EGFR, Her2/Neu, Her3 and Her4.   Binding 
of ligand to these receptors causes hetero-dimerization of the receptor and activation of 
both the MAPK and AKT pathways (53).  While Her2/Neu does not have any known 
direct ligands, it is known to function as a binding partner with ligand-bound EGFR, 
Her3 or Her4. Normal Her2 expression is important for both normal cell growth and 
differentiation with Her2 over-expression known to occur in many types of cancers, 
including 20-30% of primary breast tumors (54-57). Over-expressing HER-2 in ER 
positive MCF-7 breast cancer cells prevents the cells from responding to Tamoxifen 
(58, 59). Though both Her2 and ligand-bound ERα can drive tumor growth, an inverse 
relationship between the over-expression of Her2 and ERα expression in breast tumors 
has long been observed (60). This observed inverse relationship has helped to inform 
the recommendation of The American Society of Clinical Oncology that all breast 
tumors be evaluated for Her2 expression as well as ERα and PR expression as the 
expression status of these receptors helps to identify how invasive and differentiated 
the tumor is, and helps to determine the best course of treatment for the patient (61-65).    
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CHAPTER 2 
IDENTIFICATION AND CHARACTERIZATION OF THE ESTROGEN 
RECEPTOR ALPHA-INTERACTING PROTEIN EUKARYOTIC 
TRANSLATION INITIATION FACTOR 3 SUBUNIT F (eIF3f) 
 
Abstract 
 In an attempt to identify interacting proteins responsible for the previously 
observed chromatin unfolding activity of apo-Estrogen Receptor alpha, we performed a 
yeast two-hybrid screen using amino acids 420-534 of ERα as bait. We identify 
Eukaryotic translation initiation factor 3 subunit F (eIF3f) as an interaction partner.  
Bimolecular Fluorescence Complementation (BiFC) microscopy suggests that in the 
absence of estradiol, ERα-eIF3f is present in discrete, perinuclear pockets, as well as in 
the nucleus.  As eIF3f is a translation factor, we explore the possibility that the 
interaction between eIF3f and ERα is a means through which estradiol can influence 
translation.  In support of this link, we find ERα in polysome profile fractions. From 
knockdown of eIF3f also appears to change the solubility of ERα within the nucleus of 
breast cancer cells.  eIF3f knockdown also results in changes in steady-state mRNA 
levels of specific estradiol-target genes. Upon isolation of mRNA following polysome 
fractionation, we observe differences in the rate of translation of several estradiol-
regulated mRNAs.  Unlike other ERα-interacting partners such as Jab1 and E6-AP, 
eIF3f interacts with a shorter form of ERα.   
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Introduction 
Initiation of translation is a tightly regulated, multi-step process.  Not 
surprisingly, dysregulation of protein synthesis is emerging as a key driver of 
oncogenesis (1-4).  The Eukaryotic initiation factor 3 complex (eIF3) is a large 
complex known to play an essential role in regulating translation.  The best 
characterized function of the eIF3 complex is its ability to form a stable complex with 
the 40S ribosomal subunit, which prevents premature association with the 60S subunit 
(5).  Additionally, eIF3 forms a ternary complex with eIF2-GT-Met-tRNA, known as 
the 43S pre-initiation complex, thereby promoting mRNA binding through interactions 
with the eIF4G subunit of the mRNA-cap binding complex (6, 7) and eIF4B (8). The 
~750 kDa mammalian eIF3 has been purified (9-11) and consists of at least 13 non-
identical subunits (designated eIF3a to eIF3m) with molecular masses ranging from 35 
to 170 kDa (12, 13).  Many individual functions have been ascribed to the subunits 
within the eIF3 complex, but how the subunits function within the complex is not 
entirely clear, though some of the structural roles of the subunits have been inferred 
through the cryo-EM reconstructions (14).  Though the number of subunits within the 
eIF3 complex differs significantly between organisms, a conserved core of subunits 
purified from S. cerivisiae can replace mammalian eIF3 in an in vitro translation-
initiation assay (11).   Depending on the organism, the eIF3 complex contains 
additional subunits believed to participate in additional roles/functions (15-21).  
Additionally, there is evidence that complexes containing different combinations of 
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core and non-core eIF3 subunits are found within the same cell and may function to 
regulate the translation of specific subsets of mRNAs (22, 23). 
The 47 kDa subunit of eIF3, designated as eIF3f, is not considered to be a core 
component of the eIF3 complex (22). Despite its not being considered to be a part of 
the core, it has been reported to have an essential role in cell viability (24).  In 
characterizing eIF3f, researchers found that it contained a Jab1/MPN (also known as 
JAMM) motif (25-27).  Possession of this motif along with other structural similarities 
suggests functional homology with the S. pombi protein Csn6, a member of the COP9 
signalsome, and the lid complex of the proteasome (25). This motif was originally 
reported to be a metalloprotease-like zinc site with catalytic activity possibly 
functioning as a de-ubiquitinating motif (26), and some proteins containing this motif 
do appear to posses such activity. Interestingly, eIF3f is not one of them, and has no 
catalytic isopeptidase activity, suggesting that the motif has a structural function 
instead but could still possibly bind ubiquitin through its JAMM motif (28). 
Other reports have identified eIF3f as possibly having a different function. 
eIF3f was found to be phosphorylated on two different residues by Cyclin-dependent 
kinase 11 (CDK11) during apoptosis (17, 29).  This phosphorylation enhanced eIF3f 
binding to the core subunits of the eIF3 complex and may help to inhibit translation 
during apoptosis. Additionally, eIF3f expression has been shown to oscillate during the 
cell cycle, peaking in expression during the S and the M phases while deregulation of 
eIF3f expression negatively affects cell viability and induces apoptosis (24).  eIF3f has 
also been shown to be a major target of the E3 ubiquitin ligase atrogin1/MAFbx, which 
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is upregulated in many cases of cancer, AIDS, sepsis and other systemic diseases, 
thereby inducing muscle atrophy (30-32).  
The ability for eIF3f to affect muscle atrophy is believed to be because of its role in 
activation of translation. Along with eIF3h, eIF3f was identified as an interacting 
protein of S6K1 through tandem-affinity purification (TAP) in an attempt to identify 
the proteins responsible for linking the mTOR/Raptor and S6K1 pathways (33). 
Separately, another group identified eIF3f in a yeast two-hybrid screen using a portion 
of mTOR as bait (34). Both groups suggested a model where eIF3f facilitated binding 
of the eIF3 complex to S6K1 under basal conditions.  Upon activation through insulin 
signaling, and presumably other mitogenic signals including hormones, eIF3f 
dissociates from S6K1, allowing for binding with mTOR/Raptor, thereby forming the 
pre-initiation complex (33, 34) and allowing for activation of translation.  
 Although the role for eIF3f3 within the eIF3 complex is yet to be defined, it is 
clear that eIF3f can function in a capacity that can significantly impact cell function 
and growth.  This point is illustrated by the fact that eIF3f is essential for viability, and 
that depleting this protein markedly decreases global protein synthesis in S. pombi (22, 
24) and is a negative regulator of translation (35).  Additionally, decreased eIF3f 
expression has been observed in tumor cells, A549 cells (human lung adenocarcinoma 
epithelial cells) as well as pancreatic cancer and melanoma cells (24, 35-37).   
 The physiological actions of estrogen, including sexual development and 
reproduction, are modulated by the estrogen receptor (ER) (38).  Apart from their roles 
in the normal physiology, estrogens are also known to play a significant role in the 
pathophysiology of breast cancer (39, 40).  As a nuclear hormone receptor, ER 
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functions as a modular transcription factor, affecting the transcription levels of 
hundreds of target genes in a variety of tissues upon binding to its cognate ligand, 17β-
estradiol (41-44).  The transcriptional response elicited by estradiol through ER is 
strongly influenced by its interacting partners (45-47).  These interacting partners 
include several different classes of chromatin remodeling proteins including (i) 
members of the p160 subfamily (SRC1 and TIF2); (ii) histone acetyl transferases 
(HATs) such as CBP/p300; (iii) histone arginine methyl transferases (HMTs) such as 
CARM1 or PRMT1; (iv) and nucleosome remodeling complexes such as SWI/SNF 
(47-49).  
 Nuclear hormone receptors function as ligand-activated transcription factors, 
utilizing a signaling molecule (i.e. 17β-estradiol) to activate transcription of their 
cognate target genes.  As typical of nuclear hormone receptors, ER contains several 
modular domains to which specific functions can be ascribed (50).  ER contains two 
transcription-activation of function (AF) domains known as AF-1 and AF-2.  The 
amino-terminal A/B domain contains a constitutive ligand independent AF1 domain 
(51) while the E domain contains the ligand-binding domain (LBD), largely 
responsible for the observed AF-2 properties.  Upon binding of ligand to the LBD, the 
AF1 domain interacts with the AF-2 domain.  This interaction is enabled by the 
flexible D domain or hinge region and is required for maximal transcriptional 
activation.  The interaction between the two AF domains helps to hold the receptor in a 
conformation that exposes the C domain, containing the DNA-binding domain (DBD). 
 Alternative splice forms of ERα have been reported to be expressed in various 
tissues, possess differing ligand affinities, and may act antagonistically towards full 
 18 
length receptor function (52).  In particular, a truncated form of ERα, ERα46 has been 
reported to be expressed in MCF-7 cells and is missing the first exon, amounting to the 
first N-terminal 173 amino acids, containing the entire AF-1 region (53, 54). Unbound 
ERα46 is reported to recruit corepressors, thereby reducing the basal transcription 
relative to full-length ERα on estrogen-target genes such as pS2 (54).   
 In collaboration with the Belmont lab, our lab previously reported that a small 
region of ERα was capable of modifying chromatin structure, independent of ligand 
(55).  In an attempt to identify potential ERα binding proteins responsible for this 
observed ligand-independent chromatin remodeling, we performed a yeast two-hybrid 
screen utilizing amino acids 420-534 of ERα as bait.  We identified Eukaryotic 
Initiation Factor 3f (eIF3f) as an ERα-interacting protein.  Though unclear if eIF3f is 
responsible for the observed chromatin unfolding by apo-ERα, we investigate the 
putative function of eIF3f-ERα interaction with respect to ERα-mediated transcription 
and translation.  
 
Materials and Methods 
Cell Lines 
MCF-7 cells were maintained in minimal essential medium (MEM; Sigma 
Chemical Co.) supplemented with 5% calf serum (HyClone), 100 µg/mL of 
penicillin/streptomycin (Invitrogen), and 25 µg/mL of gentamicin (Invitrogen). The 
human embryonic kidney cell line HEK 293T (293T) was purchased from the ATCC 
(Manassas, VA) and maintained in Dulbecco's Modified Eagle Medium (DMEM; 
Sigma Chemical Co.), 10% fetal bovine serum (HyClone), 100 µg/mL of 
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penicillin/streptomycin (Invitrogen), and 25 µg/mL of gentamicin (Invitrogen). 
Chinese hamster ovary (CHO) cells were maintained as previously described (56). 
A03_1 CHO DG44 were maintained as previously described (55).  Prior to 
experiments, cell were grown in phenol-free MEM or DMEM, supplemented with 5 or 
10% charcoal dextran-treated calf (CD-CS) or fetal bovine serum (CD-FBS) for a 
minimum of two days. 
 
Western blot analysis   
Whole-cell extracts were prepared by harvesting cells directly into 2× SDS-
PAGE sample buffer containing 125 mM Tris pH 6.8, 20% glycerol, 4% SDS, 0.02 
mg/ml bromophenol blue and 5% β-mercaptoethanol.  Protein (25-100 µg)was 
separated on 4-20% SDS-PAGE gels (Bio-Rad) and transferred to nitrocellulose 
membranes.  Antibodies were purchased from the following companies: ERα (HC-20; 
sc-543) and Lamin A/C (N-18; sc-6215) from Santa Cruz Biotechnologies, β-actin 
(No. A2228) and Monoclonal ANTI-FLAG M2 ( No. F1804) from Sigma-Aldrich. 
eIF3f monoclonal antibody was generously provided by Dr. Jiaqi Shi at the University 
of Arizona. ERα antibody was generously provided by Dr. Geoffrey L. Greene at the 
University of Chicago.  Secondary antibodies were purchased from Jackson 
Laboratories and were used per manufacturer’s instructions.  Detection was performed 
using SuperSignal West Pico or Femto Chemiluminescent Substrate. 
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RNA isolation, reverse transcription, and real-time PCR  
Cell RNA was prepared using TRIzol reagent (Invitrogen) according to the 
manufacturer’s recommendations. RNA samples were reverse-transcribed in a total 
volume of 20 µL using 200 units of reverse transcriptase, 50 pmol of random hexamer, 
and 1 mmol/L of deoxynucleotide triphosphates (New England Biolabs). The resulting 
cDNA was then diluted to a volume of 500 µL with nuclease-free water. Real-time 
PCR was performed on an ABI Prism 7900HT instrument using SYBR Green PCR 
Master Mix (Applied Biosystems) according to the manufacturer’s recommendations. 
Briefly, each PCR contained 1× master mix, 4 µL of the diluted cDNA reaction, and 50 
nmol/L of forward and reverse primers designed to yield 80- to 125-bp amplicons. 
PCR was carried out through 40 cycles (95°C for 15 s, 60°C for 1 min) following an 
initial 10-min incubation at 95°C. Relative expression levels were calculated as 
described previously, using acidic ribosomal protein 36B4 mRNA as an internal 
control (57, 58). 
 
Small interfering RNA studies 
Small interfering RNA (siRNA) duplexes targeting eIF3f (ON-TARGETplus 
SMARTpool no. L-019535-00-20) or GFP  (no. P-002048-01-20) were obtained from 
Dharmacon and transfected into cells at a final concentration of 20-50 nmol/L using 
DharmaFECT transfection reagent according to the manufacturer’s recommendations. 
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Yeast Two-Hybrid Screen 
The yeast strain SKY543 (a derivative of PJ69-4A) that was also ade2- was 
used. Similar to PJ69-4A, cells were MATα trp1-901 leu2-3,112 ura3-52 his3-200 
gal4Δ gal80Δ LYS2::GAL1-HIS3 GAL2-ADE2 met2::GAL7-lacZ.  The yeast strain 
was kindly given Dr. David Rivier. pBD-Gal4-ER420-534 was used as bait with a Human 
Mammary Gland MATCHMAKER cDNA library (Clontech), utilizing the pACT2 
vector containing the Gal4 Activation Domain. Salmon Sperm DNA was used as a 
carrier. Approximately 2.4x104 colonies were screened. The yeast were transformed 
following Clontech MATCHMAKER protocol, and were grown on dropout media 
devoid of leucine, tryptophan and adenine. β-galactosidase activity was observed by 
visual identification of red colonies. To recover library plasmids, total DNA positive 
colonies was isolated by use of the Y-DER kit (Pierce) and transformed into E. coli 
(DH5α). The plasmid was then sequenced using standard sequencing methods.  
 
Mammalian Two-Hybrid Assay 
Full-length eIF3f was inserted into the pM vector of the Mammalian 
Matchmaker two-hybrid assay system (Clontech).  pCMV5-VP16-ERαDEF was 
previously generated in our lab (59). The Dual-Luciferase Reporter (DLR) Assay 
System (Promega) was used along with the pGL3 vectors for both Firefly and Renilla 
luciferase.  Transient transfections in Chinese Hamster Ovary (CHO) cell were 
performed as previously described (60). 
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GST pull-down Assays 
Full-length eIF3f along with eIF3f 1-198 and eIF3f 198-300 were inserted into 
the pET15b vector. GST-ERαDEF was created by insertion of the DEF domain of ERα 
into the pGEX-4T-1 expression vector (Amersham Pharmacia).  pGEX-ERαDEF was 
transformed into E. coli BL21(DE3) (Novagen). Bacterial culture (1000 ml) expressing 
the recombinant GST fusion protein was grown at 37°C to an OD600 of 0.6, then cooled 
to 25°C. The cells were treated with 0.1 mm  isopropyl-b-D-thiogalactopyranoside 
(IPTG) at an OD600 of 1.0. for 3.5 hours. Following centrifugation, purification of 
GST-ERαDEF was then performed by freeze/thaw cycle and disrupted by multiple 
passes through an Avestion C5 French pressure cell. Following lysis, cellular debris 
was removed by centrifugation. The supernatant was then applied to a glutathione 
sepharose (Amersham Pharmacia) column that had been equilibrated in 1X phosphate-
buffered saline (PBS) (pH 7.4), 500 mM KCl, at a flow rate of 0.5 mL/min. The 
column was then washed at a flow rate of 2 mL/min for 150 min with the same 
equilibration buffer. The sample was then eluted using 20 mM reduced glutathione, 
200mM Tris (pH 8.3), and 500 mM KCl. Fractions (10 mL) were then analyzed by 
SDS-PAGE. Fractions containing GST-ERαDEF were then dialyzed in 20 mM MES 
(pH 6.5), 100 mM KCl (buffer A), using a 6000–8000 molecular-weight cutoff 
(MWCO) dialysis bag. GST pull-down assays were then performed per the instructions 
of the manufacturer, and as previously described (61).  
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Co-Immunoprecipitation Assays 
293T cells expressing the desired constructs and treated with the corresponding 
ligands were frozen and thawed three times prior to addition of lysis buffer (10 mM 
HEPES, pH 7.6, 100 mM potassium glutamate, 2.5 mM DTT, 10 mM magnesium 
acetate, 5 mM EGTA, 3.5% glycerol, 0.003% NP40). Following centrifugation, the 
cleared lysates were then incubated with ANTI-FLAG M2 Affinity Gel (Sigma) that 
had been equilibrated in the aforementioned lysis buffer.  Following 4 hours of 
incubation, the agarose beads were then centrifuged and washed three times.  
Precipitated proteins were then eluted by the addition of SDS-PAGE sample buffer 
before being resolved via SDS-PAGE.  
 
Fluorescence Microscopy 
Fluorescence Microscopy was performed as previously described (55). Briefly, 
cells were stained in PBS* solutions (PBS-5 mM MgCl2-0.1 mM EDTA). Cells were 
rinsed in PBS*, permeabilized for 60 seconds in 0.1% Triton X-100, and fixed in 1.6% 
formaldehyde (Polysciences) for 30 min at room temperature. Coverslips were washed 
for 5 min in 0.1% Triton X-100, three times (5 min each) in PBS*, three times (5 min 
each) in 20 mM glycine, 5 min in 0.1% Triton X-100, and 1 hour at room temperature 
in SuperBlock (Thermo Scientific).  Primary antibody was incubated overnight at 4°C 
in SuperBlock.  Following 3 washes (5 min each) with the PBS*, secondary antibody 
(Alexafluor 546; Cat. No. A11010, Invitrogen) was incubated in SuperBlock for 6 
hours at 4°C.  Coverslips were again washed 3 times (5 min each) and mounted using 
VECTASHIELD Hardset containing DAPI (Vector Labs) per the manufacturer’s 
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instructions. Images were taken using a Zeiss Axiovert 200 M inverted compound 
microscope with a C-Apochromat 40x/1.2 W objective, Axiocam HRm digital camera 
and Axiovision acquisition software. 
 
Bi-fluorescence Complementation 
 Bi-fluorescence Complementation (BiFC) was performed via an adapted 
protocol from the Kerppola lab (62). COS-1 cells were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) (Hyclone, Logan, UT) supplemented with 10% 
fetal bovine serum with penicillin and streptomycin in 6-well plates at 37°C. Cells 
were weaned in 10% charcoal dextran stripped serum DMEM for three days prior to 
screening.  300 ng of both corresponding VN173- and VC155-fusion construct were 
transfected using Lipofectamine 2000 (Invitrogen) per the manufacturer’s instructions.  
As an internal control, 50 ng of ECFP containing an attached NLS, was cotransfected.  
24 hours after transfection, and following the corresponding ligand treatment, cells 
were washed, fixed and mounted as described above, using VECTASHIELD Hardset 
(Vector Labs) per the manufacturer’s instructions. Images were also taken as described 
above. 
 
Sequential Protein Extraction from Cells 
Extraction was performed as described by Stenoien et al (63). Cells were 
washed in PBS and sequentially treated in the following manner: soluble proteins were 
extracted by treatment for 3 min with ice-cold cytoskeletal buffer (CSK; 10 mM 
PIPES, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2 and 0.5% Triton X-100, pH 
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6.80) containing protease inhibitors (aprotinin, leupeptin, pepstatin A, antipain, 
phenylmethylsulphonyl fluoride (PMSF). Chromatin was removed by digesting with 
RNAse-free DNAse I (400 U ml–1, Boehringer) in digestion buffer (CSK plus 50 mM 
NaCl) containing protease inhibitors for 30 min at 32 °C. The DNAse I digestion 
buffer was removed and replaced with 187.5 ml of fresh digestion buffer; 1 M 
ammonium sulfate was then added drop-wise to a final concentration of 0.25 M and 
cells were incubated for 5 min at room temperature. The ammonium sulfate was 
removed and replaced with 125 ml of digestion buffer; 4 M NaCl in digestion buffer 
was then added to a final concentration of 2 M NaCl and cells were incubated 5 min at 
room temperature. 
 
Polysome Profiling 
 Polysome profiling was performed via a modified protocol from Blackwell et al (64). MCF-7 cells were to approximately 60% confluency in150 mm dishes. Prior to 
harvest, cells were treated for 15 min with cycloheximide (100 mg/ml). Linear 15–45% 
sucrose gradients were prepared with buffer containing 100 mM KCl, 20 mM Tris (pH 
7.5), 5 mM MgCl2 using a gradient maker (BioComp). Cells were washed in PBS, 
then lysed in the aforementioned buffer supplemented with 0.3% Igepal CA-630 and 
centrifuged for 10 min at 20 000 g at 4°C. Postnuclear supernatants were overlaid on 
the gradient and centrifuged for 75 min at 188 000g at 4°C. Each gradient was 
fractionated into 1 ml fractions by bottom displacement using a gradient fractionator 
(Isco) with the ribosomal profile monitored at 254 nm. 
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Results 
Yeast Two-Hybrid Screen 
We decided to test the hypothesis that the chromatin remodeling activity of 
ERα was due to interaction with another chromatin remodeling protein.  In 
collaboration with the Belmont lab, amino acids 420-534 were identified as possessing 
the greatest level of ligand-independent chromatin remodeling (65). We thus employed 
a yeast two-hybrid screen, using amino acids 420-534 from ER as bait, fused to the 
Gal4 DNA-binding domain.  The resulting plasmid, pBD- ER420-534 was then screened 
against a normal breast cDNA library. Of 30 resulting clones, 19 were identified as in-
frame cDNAs of eIF3f (table 2.1). Many of the eIF3f clones were missing the first 5-20 
amino acids, but did contain the complete 3’ coding sequence. A full-length eIF3f 
construct was made by oligo addition of both the missing 5 amino acids and 6 UTR 
bases. 
In order to confirm the interaction between pBD- ER420-534 and the identified 
eIF3f target (pAD-eIfe3f), we re-introduced both plasmids back into yeast and grew 
them on selective media. Yeast transformed with both the bait and target constructs 
were able to growth on the selective media, and were also capable of activate 
transcription of β-galactosidase, a reporter gene present in the yeast strain under the 
Gal4 promoter control, further demonstrating the specificity and strength of the 
interacting fusion proteins.  
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Mammalian Two-hybrid Assay 
We next utilized a mammalian two-hybrid system in Chinese Hamster Ovary 
cells to further demonstrate and confirm the interaction between ER and eIF3f (Figure 
2.1).  In this experiment, rather than use ERα amino acids 420-534, which is unlikely 
to bind estradiol well, we used the DEF region of ERα, which is known to bind 
estradiol with approximately the same affinity as that of the full length ERα (John and 
Benita Katzenellenbogen—personal communication).    Additionally, using a larger 
region of ERα, known to be capable of binding estrogen would more closely resemble 
full-length ER in terms of conformation, thus lessening the chance that proteins 
interacting with ER420-534 were artifacts.  We thus tested the interaction between eIF3f 
fused to a DNA binding domain on the N-terminus (pM-eIF3f) with a fusion construct 
containing the acidic activator VP16 and the DEF domain of ERα (VP16-ERDEF).  In 
the presence of estradiol, we observed a slight increase in luciferase activity upon 
transfection of the control pM construct and VP16-ERDEF (column 1).  In the absence 
of estradiol, we observed no significant increase in luciferase activity upon co-
transfection of pM-eIF3f and VP16-ERDEF (column 5, vehicle treated). With these 
same two expression constructs, we observed an approximately 3-fold increase in the 
luciferase activity in the presence of 10 nM estradiol (column 5, E2 treated).  The 
ligand-dependent increase in luciferase activity observed following co-transfection of 
both eIF3f and ERDEF was significantly higher than seen with VP16-ERDEF alone.  As 
ER is a known transcriptional activator, the reciprocal experiment could not be 
performed because pM-ERDEF in the presence of estrogen is capable of activating 
transcription of the luciferase reporter. This intrinsic transcriptional activity may also 
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help to explain the increase in luciferase activity upon transfection of VP16-ERDEF in 
the presence of estradiol.  As a positive control, we co-transfected the ERα co-activator 
SRC-1 along with ERDEF.  As expected, luciferase activity increased in an estradiol-
dependent manner (column 6).  
 
GST Pull-down Assay   
To further characterize the interaction between eIF3f and ERα, we used a GST 
pull-down assay.  In this assay, in addition to using full-length eIF3f inserted into the 
pET expression vector, we also divided eIF3f into two halves, testing the interaction of 
all eIF3f constructs with a bacterial-produced GST-ERDEF protein.  As a positive 
control for interaction with GST-ERDEF, we used a full-length member of the known 
ERα co-activator, SRC-1, inserted into the same pET expression vector (Figure 2.2A, 
lanes 1-4).  As seen in figure 2.2, upon addition of 10 nM estradiol, there is a ligand 
dependent interaction between pET-SRC-1 and GST-ERDEF (lane 3 compared to lane 
4).   We then looked at the interaction between full-length eIF3f.  As a negative 
control, we found that eIF3f alone demonstrated some association with GST alone 
(lane 6).  This interaction with GST had been previously reported (34).  Despite this 
weak association with GST alone, we observed a significant increase in eIF3f pull-
down with GST-ERDEF in both the presence and absence of 10 nM estradiol (Figure 
2.2A, lanes 7 & 8).  The amount of eIF3f  associated with GST-ERDEF did not appear 
to change with the addition of estradiol. We next looked to see which half of eIF3f was 
capable of binding to GST-ERDEF.   We chose to separate eIF3f at amino acid 198 as 
all known functionally characterized regions are contained within the first 198 amino 
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acids.  Serine 46 and threonine 119 are known to be phosphorylated by cyclin-
dependent kinase 11 (CDK11) during apoptosis (17, 29).  Additionally, the first half of 
eIF3f contains an MPN motif, which is part of a larger motif known as JAMM, which 
has been shown to stabilize the interaction between the progesterone receptor (66) and 
the p160 protein family member SRC-1 (67).  To our surprise, both halves of eIF3f 
appeared to interact equally well with GST-ERDEF (Figure 2.2B, lanes 3-5).  
Furthermore, there was no observed difference in association between eIF3f and GST-
ERDEF in the presence or absence of estradiol nor did the anti-estrogen ICI 182780 
appear to affect interaction (lanes 3-5).   Interestingly, neither eIF3f 1-198 nor eIF3f 
199-360 interacted with GST alone, in contrast to the observed interaction between 
GST-ERDEF and full-length eIF3f (lanes 2 & 3-5).   
 
Co-immunoprecipitation Assay 
 We next looked at eIF3f interaction in a more in vivo-like setting by doing co-
immunoprecipitation assays in Human Embryonic Kidney (HEK)-293T cells.  For 
these assays, we linked full-length eIF3f with a C-terminal 3x Flag epitope tag.  As 
HEK-293T cells do not endogenously expresses ERα, full-length Flag-eIF3f along 
with full length ERα were transiently expressed from their corresponding mammalian 
expression vectors.  Cell lysates were then subjected to immuno-precipitation with M2-
antibody linked agarose beads.  The resulting immuno-complexes were then resolved 
via SDS-PAGE and immuno-blotted for ERα.   In both the presence and absence of 10 
nM estradiol, Flag-eIF3f effectively co-immunoprecipitating ERα (Figure 2.3A, lanes 
1 &2).  We next compared the observed interaction between ERα and eIF3f to other 
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known interacting proteins for which a function has been characterized.  For this 
purpose, we looked at the protein Jab1 since it contains a MPN motif also present in 
eIF3f and has been reported to facilitate ERα turnover in MCF-7 cells in a ligand-
dependent manner (lanes 3 & 4) (68).  Additionally, we looked at the E3 ubiquitin 
ligase E6-associated protein (E6-AP) (lanes 5 & 6), also reported to be involved in 
degradation of ERα in a ligand-dependent manner (69-73). We were able to observe a 
significant association between Jab1 and ERα as well as E6-AP and ERα.  These 
interactions did not appear to depend on the presence of ligand for their interaction in 
the same manner as SRC-RID interaction with ERα appeared to be ligand dependent.  
Changes in the amount of associated protein appear to be in proportion to the input 
protein. Similar to Jab1 and E60-AP, eIF3f interaction with ERα did not appear to be 
dependent on the presence of estradiol.   
 Interestingly, we observed different amounts of degraded, or possibly truncated 
ERα bands in the input lanes, depending on what protein is co-expressed as well as 
whether or not estradiol is present (ERα input lanes 1-8).  The intensity of the smaller 
bands always appears to be proportional to the amount of ERα found at the expected 
size of 66 kDa. Also, the banding pattern does not appear to be different with eIF3f, 
Jab1 or E6-AP co-expression.   These banding patterns in the input lanes stand in 
contrast to those in the ERα precipitated lanes—in which eIF3f is the only protein 
capable of co-immunoprecipitating any of these smaller sized bands. 
Immunoprecipitation of these smaller ERα bands stands in contrast to the observed 
precipitation of a larger ERα product when the E3 ligase E6-AP is co-expressed (top of 
lanes 7 & 8).  
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 We then turned to MCF-7 cells to determine if ERα interacted with eIF3f under 
endogenous conditions. MCF-7 cells express a high level of ERα which we 
immunoprecipitated with the D12 antibody from Santa Cruz, and then immunoblotted 
with an antibody to eIF3f.  Independent of the presence of estradiol, we observed an 
interaction between endogenous ERα and endogenous eIF3f (Figure 2.3B, lanes 5 & 
6).  As a positive control, we attempted to co-immunoprecipitate the coactivator SRC-
3.  While we were able to observe co-immunoprecipitation, we did not observe the 
predicted ligand-dependent interaction.  The amount of SRC-3 precipitated with ERα 
was reflective of the total SRC-3 found in the crude lysate input.  
 
Fluorescence Microscopy  
Exogenously expressed eIF3f containing an HA tag has been reported to be 
found in both the nucleus and cytosol of the human melanoma cell line A375 (17).  In 
S. pombi, exogenously expressed eIf3f containing an N-terminal GFP tag was reported 
to be exclusively cytosolic (22).  We therefore wanted to determine the location of 
eIF3f in MCF-7 breast cancer cells. Using an antibody directed at endogenous eIF3f, 
we found it to be located in both the nucleus and the cytosol, though it appeared that a 
greater concentration of the protein was found in the cytosol, with some areas more 
intense in concentration than others (Figure 2.4A).  
As eIF3f interaction with ERα began in a search for ERα-interacting proteins 
capable of ligand-independent chromatin unfolding, we went back to the original 
system in which this chromatin unfolding was observed to see if eIF3f was found in the 
same lac operator array to which tethered ERα could change the chromatin 
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conformation.  We utilized the same CHO A03 cells containing this array and 
transiently expressed both the lac repressor ERα fusion protein along with Flag-tagged 
eIF3f from their respective mammalian expression plasmid constructs (Figure 2.4B).  
Cells in which both lac repressor ERα and eIF3f were expressed, we found a 
significant enrichment of eIF3f at the ERα-bound lac operator array in the absence of 
ligand.  This enrichment was no longer apparent upon addition of 10 nM estradiol.  
These results suggest that estradiol can influence the interaction between eIF3f and 
ERα within the nucleus.  
 
Bi-fluorescence Complementation 
Having observed eIF3f interaction with ERα in a variety of in vitro and in vivo 
conditions, we next turned to fluorescence microscopy to observe interaction between 
these two proteins.  To monitor this interaction, we utilized the bi-fluorescence 
complementation assay (BiFC) in which a modified enhanced yellow fluorescence 
protein (EYFP) known as the Venus EYFP is split into two parts (62, 74, 75).  Each 
half the EYFP protein is fused to a target protein of interest—in this case ERα and 
eIF3f.  Independently, neither of the fusion protein constructs will fluoresce.  But if the 
two proteins of interest interact with each other, the two EYFP halves will come 
together, resulting in a fluorescent signal.  We thus transfected fusion constructs 
pVC155-eIF3f and pVN173-ERα along with a control vector containing a nuclear 
localization sequence attached to enhanced cyan fluorescence protein (p-ECFP-NLS).   
The pECFP-NLS serves a dual purpose by indicating both the expression efficiency of 
the transfected constructs as well as to distinguish the nucleus from the cytosol, given 
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it’s restricted location to the nucleus.  Cells in which all three constructs were 
appreciably expressed contained an EYFP signal predominantly in the nucleus. While 
the signal was strongest in the nucleus, we also observed several discrete small pockets 
of fluorescence outside the nucleus. It appeared that eIF3f-ERα interaction was 
predominantly in the nucleus, where ERα is known to typically reside (Figure 2.5A). 
As eIF3f was observed to be present through out the cell, including the nucleus, the 
observed interaction between the two proteins in the nucleus is consistent with the 
known sub-cellular locations of both interacting proteins.    
We also looked at whether or not estradiol could influence the location of the 
eIF3f-ERα interaction.  Addition of 10 nM estradiol did not appear to alter the 
distribution of the two interacting proteins within the nucleus. Interestingly, the 
observed pockets of eIF3f-ERα interacting proteins outside the nucleus disappeared 
upon ligand treatment (Figure 2.5A).  In order to further observe ERα interacting 
dynamics with the BiFC, we also looked at ERα dimerization by transfecting two 
different ERα constructs, each containing one half of the EYFP protein.  Upon 
estradiol treatment, we did not see any appreciable change in ERα distribution.  It 
should be noted that upon association of the two EYFP halves, the kinetics of the 
interaction is such that the two halves stay predominantly associated and would not be 
reflective of typical ER dimer association. None the less, upon addition of the ligand 
ICI 182780, as expected, ERα dimers moved completely out of the nucleus, thus 
demonstrating that the different association kinetics, dictated by the two EYFP halves, 
did not preclude nuclear export in the presence of ICI 182780.  
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eIF3f changes cellular solubility of ERα    
 Upon performing the co-immunoprecipitation assays in HEK-293T cells, we 
observed a significant decrease in the amount of ERα in the presence of estradiol.  In 
performing these experiments, the cells are transfected 24 hours before ligand 
treatment in order for proper expression of the desired exogenous proteins. Forty-five 
minutes prior to harvesting the cells, ligand, including 10 nM estradiol is added.  
Seeing as this is a relatively short time for estradiol treatment, and that estradiol is 
known to shorten ERα half-life to between 3-5 hours (76), we looked to see if there 
was another possible explanation for the decrease in co-immunoprecipitated protein in 
the presence of estradiol.  To demonstrate that degradation alone could not account for 
the change in ERα protein levels, we performed the same experiment, only this time 
treating with estradiol for 10 minutes. We found the same decrease in ERα protein 
levels.  As this change in protein levels occurred at such an early time point, we 
explored the hypothesis that the change of harvested protein was due to changes in 
ERα solubility.   
Changes in ERα solubility upon exposure to estradiol were previously reported 
by Stenoien et al. (63).  Using the same protocol employed by Stenoien, we chemically 
fractionated the cell lysate by sequential extraction.  After first obtaining whole cell 
extract with a standard lysis buffer, we subjected the remaining insoluble portion to 30 
minutes of DNase treatment, and subsequent repeat of lysis buffer extraction.  The 
final remaining insoluble portion was then subjected to a 2.0 molar NaCl solution to 
extract the remaining proteins from the insoluble nuclear matrix.  This process resulted 
in three fractions: whole cell extract, DNase treated and the high salt fraction. As seen 
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in figure 2.6, treatment with 10 nM estradiol greatly increased the amount of ERα in 
the high salt fraction compared to vehicle treated, consistent with the observations of 
Stenoein et al (compare lanes 3 & 6).  Estradiol treatment also appeared to result in 
additional, smaller bands (50 kDa and 28 kDa) in the DNase treated fraction (lanes 5 & 
6,). We then utilized siRNA directed at eIF3f to reduce the amount of eIF3f protein.  
Upon eIf3f knockdown, we observed significantly more ERα protein in the vehicle 
treated, whole cell extract, compared to siRNA control treated (lanes 7-12).  We also 
observed and increase in ERα protein found in the high salt fraction with eIF3f 
knockdown (lane 12).  Additionally, the smaller bands previously found in the 
estradiol / DNase treated fraction were no longer present in the DNase treated eIF3f 
knockdown fraction (compare lanes 5 & 11).  
We next looked at the effect of the proteasome inhibitor MG132 on ERα 
solubility with and without estradiol along with eIF3f knockdown. MG132 treatment 
had the greatest impact on ERα protein levels in the vehicle treated, high salt fraction 
(lane 3).  Similar to what we observed with the bands in the DNase treated sample, 
eIF3f knockdown and estradiol treatment eliminated the presence of any of the smaller 
bands (compare lanes 5 & 11).  Despite an increase of ERα protein in the eIF3f 
knockdown, MG132-treated samples for both vehicle and estradiol-treated high salt 
fractions, ERα protein levels decreased with MG132 treatment (compare lanes 3 & 9).  
Presence of the smaller ERα bands did not disappear upon MG132 protein, suggesting 
that the bands are not products of proteasome-mediated ERα degradation.  Together, 
these experiments demonstrate that ERα protein solubility changes depending on eIF3f 
protein levels in conjunction with estradiol.  
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Knockdown of eIF3f reduces select ERα transcriptional target genes 
 Despite eIF3f having a known function as a regulator of translation, we decided 
to see if eIF3f was also capable of impacting steady-state mRNA levels of known 
estrogen-regulated genes. To this end, we utilized siRNA directed at eIF3f to reduce 
eIF3f mRNA levels and subsequent protein levels within the cell. siRNA directed at 
eIF3f was able to substantially reduce eIF3f mRNA at both early (2 hour) and later (24 
hour) time points (Figure 2.7).  We then looked at eIF3f protein levels to see the 
reduction in protein.  We observed significant reduction in eIF3f protein.    We also 
observed a difference in the amount of eIf3f protein in our whole cell extract 
depending upon 10 nM estradiol treatment.  It was unclear if this was due to 
differences in eIF3f protein availability (solubility) or if this was a function of the 
siRNA.  We did not perform any follow up experiments to determine the cause.   
eIF3f knockdown resulted in differential transcriptional regulation of known 
estradiol-regulated genes in MCF-7 cells.  We observed significant changes in steady-
state mRNA levels with eIF3f knockdown in pS2, GREB-1 and CA-12, all known 
estrogen-regulated genes (Figure 2.7B) .  pS2 mRNA levels were most affected at 2 
hours, demonstrating 2-fold reduction in steady-state mRNA levels.  This difference 
did not persist as, after 24 hours of estradiol treatment, the steady-state levels became 
indistinguishable from control siRNA. This trend of eIF3f knockdown impacting 
steady-state mRNA levels only at the early time point was also observed with both 
GREB-1 and CA-12 (Figure 2.7B).  These changes in known ERα-transcriptional 
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targets were not global as we observed no significant change in estradiol regulation 
with eIF3f knockdown in two genes: c-Myc and TGFβ-3 (Figure 2.7C).   
Additionally, we went back to our Mammalian two-hybrid data to see if eIF3f 
over-expression impacted luciferase mRNA expression.  As we were using a dual-
luciferase system, we looked to see if constitutively expressed luciferase was altered by 
the presence or absence of any eIF3f constructs.  We observed no significant pattern of 
luciferase expression with eIF3f over-expression.  We thus conclude that eIF3f does 
not impact the constitutive expression of the Renilla luciferase.  
 
Potential role of eIF3f-ERα interaction in translation 
 As eIF3f has a known role in the initiation of translation, we next looked to see 
if we could observe a functional consequence to the interaction between eIF3f and 
ERα. To this end, we looked at the co-fractionation of eIF3f and ERα following 
sucrose density fractionation and polysome profiling.  
 Polysome profiling required growing a large amounts of cells following an 
estradiol time-course and subjecting the cells to 100 µl/ml cyclohexamide to stop 
translation.  Cells were then harvested, washed and lysed resulting in a crude cellular 
extract.  This extract is then separated on a sucrose density gradient and the protein 
absorbance is measured at 254 nm while being collected in 1.0 mL fractions.  This 
process creates a profile of the absorbance of the protein amounts in a manner that 
allows for discernment of the various soluble proteins from free ribosome and 
polysome fractions.  As seen in figure 2.8, the 15-45% sucrose density gradient 
resulted in a good separation of the free-ribosomes from the polysomes.  The 
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distinction among the soluble proteins and the free ribosomes, in the vehicle treated 
profile, was less prominent, though enough to see a discernable difference.  Following 
20 minutes of estradiol treatment, we observed a decrease in the magnitude of the 
polysomes compared to vehicle (Figure 2.8A).  We next looked at the separate 
fractions for the presence of eIF3f and ERα.  As expected, eIF3f was found in the early 
fractions, as it is known to function in the pre-initiation complexes as well as the 
soluble protein fraction (Figure 2.8B).  Estradiol treatment did not appear to change the 
location or amount of eIF3f within the fractions.  ERα was also found to be present in 
the early fractions.  This is somewhat expected in that ERα would predictable be part 
of the soluble proteins.  A significantly lower amount of ERα immuno-blot was found 
in the free ribosome fractions after 20 minutes of estradiol treatment.  More over, there 
was a substantially higher amount of the 46 kDa band, the same size found in the co-ip 
as well as the sequential extractions, in the polysome preps than in the fractions found 
in typical crude cell extract.  
 We next compared the polysome profiles of the 4 hour and 24 hour estradiol 
treatments.  Following the observed decrease in polysomes after 20 minutes, we 
observed an increase in the amount of polysomes at both 4 and 24 hours, suggestive of 
an increase in global translation with estradiol treatment.   
 We next looked to see if we could observe changes in the rates of translation of 
previously reported estrogen target mRNAs, knowing that estradiol treatment alone 
impacts transcription levels.  To do this, we started with a portion of the original 
cytosolic extract prior to sucrose density centrifugation.  We isolated the mRNA and 
performed quantitative-PCR, using the house keeping gene 36B4 for normalization.  
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As seen in Figure 2.9 we observed a regulation pattern consistent with previously 
reports in MCF-7 cells for all selected genes.  
Next, we separated the fractions collected following centrifugation into two 
pools: free ribosome and polysome-associated.  Again, we isolated and reverse-
transcribed the mRNA collected from these samples.  Q-PCR of the two pools was 
then used to observe the amount of gene-specific mRNA found in the free-ribosome 
(not actively translated) and polysome-associated (actively translated) fractions.    
From this data, we then set out to calculate the changes in the rate of 
translation, accounting for any change in the steady-state mRNA level due to estradiol 
treatment (Figures 2.8 & 2.9).  This was done by taking the mRNA value found in the 
polysome-associated fraction following 20-minutes of estradiol treatment, divided by 
the total amount of mRNA found in the cytosolic extract.  To know the change in the 
translation rate, we took this value and divided it by the amount of mRNA found in the 
vehicle treated, polysome-associated fraction.  This change in translation is performed 
for each time-point, always comparing the polysome-associated value of the time-point 
to the vehicle-treated, polysome associated value.    
This analysis gives us a picture of the change in the rate of translation of each 
individual mRNA tested, while considering the changing amount of steady-state 
mRNA due to estradiol-mediated changes in transcription. Looking at the classic 
estrogen-upregulated gene, TFF1, we see that with the large increase in steady-state 
mRNA, the trend for translation rate is either unchanged, or possibly decreased over 
time.  Other genes show different patterns. GREB-1 for example, shows significant 
increase in steady-state mRNA levels and shows increases in polysome association 
 40 
after 24 hours of estradiol treatment.  Another mRNA we looked at, CXCR4 is known 
to not change steady-state mRNA levels with estradiol treatment, but the protein level 
is known to increase with estradiol treatment.  Our results show that the rate of 
translation of the CXCR4 transcript increases at 24 hours, consistent with the observed 
increase in CXCR4 protein previously reported by our lab (77).  Two other genes, 
known to be upregulated by estradiol at early time points are c-Myc and Fos are 
observed to increase their polysome association only at later time points.  We also 
looked at a few cell cycle genes: cyclin G2 which is known to be repressed by 
estradiol, cyclin D1 which is known to be stimulated by estradiol at later time points, 
and cdk11 which appeared to be repressed by estradiol.  Both cyclin D1 and G2 did not 
increase their polysome association over time, and at early time-points appeared to 
actually decrease.  cdk11 total mRNA decreased over time, but increased in polysome 
association.   
 We also looked at polysome association for the ESR1, the mRNA for 
ERα.  As previously reported, estradiol modestly repressed ESR1 steady-state levels.  
But, over time, estradiol treatment resulted in a significant increase in ESR1 polysome 
association (Figure 2.9).   
 
Discussion 
 In an attempt to identify ERα interacting partners responsible for the observed 
chromatin unfolding activity of apo-ERα, we performed a yeast two-hybrid screen with 
ER420-534 as bait.  The highest represented protein found to interact with this portion of 
ERα was a translation factor, eIF3f.  While the interaction between ERα and a 
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translation factor suggests a tantalizing connection between transcriptional and 
translational regulation, it is unclear if the observed interaction functions in impact 
translation, or if it functions in another capacity such as chromatin unfolding.  It is also 
possible that the role of eIF3f interaction with ERα is related to both functions.   
Several of the other identified clones in the yeast two-hybrid screen also 
presented interesting possible connections to known ERα functions.  PEX5, the only 
other clone to have more than one hit, is a peroxisome receptor, and functions to escort 
cargo proteins to, or possibly across, the peroxisome membrane (78).  RAD9A is a 
DNA damage repair protein that has been shown to interact with and repress 
transactivation of the Androgen Receptor in prostate cancer cells (79).  We confirmed 
interaction of RAD9A with ERα in GST pull-down assays, but did not pursue 
characterizing the interaction because we were more interested in the possible 
connection of a translation factor with a transcriptional regulator.  Mammaglobin is 
interesting because it is a protein that is expressed almost exclusively in the normal 
breast epithelium and human breast cancer (80-82). FBLN2 has a known connection to 
estradiol in that has been reported to bind sex hormone-binding globulin (SHBG), 
thereby sequestering estradiol in the endometrial stroma, controlling sex-steroid access 
to target cells (83, 84).   PMF1 is an interesting hit in that it is involved in polyamine 
homeostasis, a key regulatory point for translation, and also has been reported to 
interact with Nrf-2 and the COP9 signalosome protein CSN7 to regulate the 
transcription of the 4E-BP1 gene, the protein of which functions as a translation 
inhibitor (85).    
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 Characterizing the interaction between eIF3f and ERα was performed using 
several different techniques.  The initial yeast two-hybrid screen yielded 19 
independent eIF3f clones, all interacting with ERα 420-534.  The high number of 
clones may be a strong indicator of the strength of interaction between eIF3f and ERα. 
Activation of the β-Galactosidase gene, under the control of Gal4 is another indicator 
of the strength of interaction between these two proteins.   
The Mammalian two-hybrid assay demonstrated that eIF3f interaction with 
ERαDEF resulted in an approximate two-fold activation of the luciferase reporter assay 
with estradiol treatment.  Given that this assay is dependent on both the transcription 
and translation of the reporter construct, and that both a transcription and translation 
factor are used for this assay, it is difficult to determine if the increased luciferase 
value was due to an increase in transcription or translation.  
The GST pull-down assay again demonstrated an interaction between eIF3f and 
ERαDEF in a ligand-independent manner.  As reported by Harris et al. (34), eIF3f was 
capable of binding GST alone, but that the presence of GST-ERαDEF resulted in a 
significant increase in eIF3f pull-down. Interestingly, this GST binding by eIF3f was 
not conserved when the protein was split into two halves.  ERαDEF binding, on the 
other hand, was conserved and as either half of eIF3f was capable of binding ERαDEF.  
 The co-immunoprecipitation assay also suggested a ligand-independent 
interaction between eIF3f and ERα. In this assay, using the full-length receptor, two 
proteins reported to increase interaction with ERα in the presence of estradiol—Jab1 
(67, 68) and E6-AP (71-73)—appeared to do just the opposite. This was most likely 
not the case as the amount of binding protein appeared to reflect the amount of 
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available protein based on the immunoblots of the input lysates, with the notable 
exception being the 46 kDa band in the estradiol co-ip with eIF3f.  Additionally, 
interaction between eIF3f, Jab1 or E6-AP with ERα could be impacted by DNA 
binding.  As the co-immunoprecipitation assay only determines interaction of 
solubilized proteins not bound to DNA, this may not be reflective of what happens in 
vivo.  To this point, both our experiments as well as those of Stenoien clearly 
demonstrate that treatment with estradiol changes the solubility of ERα.  This is likely 
due to increased binding of ERα to estrogen response elements with the DNA. As these 
proteins are known to facilitate degradation of ERα (67, 68, 71-73), it’s possible that 
the decreased amount of ERα protein was due to degradation.  While the lysates were 
harvested after only 15 minutes of estradiol treatment, incubation of the lysates with 
the M2-Flag agarose beads occured for 4-6 hours at 4 degrees Celsius and degradation 
could occur during this time. It is also well known that the ERα interacting proteins 
change with ERα binding to DNA as evidenced by the many ChIP assays performed in 
looking at transcriptional regulation by ERα.  It is therefore likely that the interacting 
proteins found in the solubilized lysates of co-ips are quite different than those found 
with ERα when bound to DNA within the cell.  Another possibility for our inability to 
observe a ligand-dependent interaction in the case of eIF3f is that diploid analysis of S. 
pombi homolog, csn6, indicated that C-terminal tagging destroyed the essential 
function of the protein (22).  
The co-immunoprecipitation assay also suggested that eIF3f was the only 
protein of the three assayed capable of binding to a shorter form of ERα.  The smaller 
46 kDa band is likely to be a shorter form of ERα as consistently disappeared from the 
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input blots in the presence of estradiol.  Of particular interest is that the input blot with 
estradiol (Figure 2.3A, lane 2) has almost none of any of the smaller bands, but in the 
co-ip, there is a significant amount of the 46 kDa band interacting with eIF3f.   
 Our observation of eIF3f and GFP-lac-ERα co-localization in CHO A03 
cells may be more reflective of the interaction dynamics in vivo.  We observed 
enrichment for eIF3 and GFP-lac-ERα on the DNA array only in the absence of ligand.  
Estradiol treatment appeared to result in eIF3f dispersing from the lac array. 
 The BiFC experiments demonstrated that interaction between eIF3f and ERα 
predominantly occurred in the nucleus.  There also appeared to be discrete areas 
outside the nucleus in which eIF3f-ERα interaction was observed.  These areas outside 
the nucleus disappeared upon estradiol treatment. We and others have demonstrated 
that eIF3f can be found in both the cytosol and the nucleus (17).   In muscle cells, 
ectopic expression of MAFbx in myotubes led to atrophy and triggered the 
translocation of eIF3f from the cytoplasm to the nucleus (30).  It’s conceivable that 
interaction between eIF3f and ERα may influence the location of either protein, 
possible a sub-population of both proteins.   
 Knockdown of eIF3f resulted in observable changes in the steady-state mRNA 
levels of specific known estradiol-regulated genes. Those genes that were affected 
appeared to be most affected at the early time point (2 hours) and were consistently 
reduced with eIF3f knockdown.  The affects of eIF3f knockdown on estrogen-
regulated mRNAs could occur through a variety of mechanisms.  Given eIF3f’s known 
function in translation, it could be that knockdown of eIF3f inhibited the translation of 
specific transcripts, thereby triggering degradation of the transcript. Alternatively, 
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eIF3f could be modulating transcription through its association with ERα.  It’s possible 
that the functional consequence of eIF3f-ERα interaction is to regulate mRNA levels 
based on transcription and translation efficiency.  To this point, we were able to 
observe changes in the rate of translation for specific estradiol-regulated genes 
following estradiol treatment.  Though we weren’t able to look at the role of eIF3f in 
the translation rate of these transcripts as the amount of siRNA required was cost 
prohibitive, we were able to observe estradiol-mediate differences in translation rates.  
 In looking at the polysome profiles of MCF-7 cells with and without estradiol 
treatment, we were surprised to see ERα in fractions other than those containing the 
soluble proteins.  Just as surprising was the large amount of the 46 kDa ERα species 
within the fractions. ERα46 is known to be expressed in MCF-7 cells (54), but not 
nearly at the levels we observed in our polysome preps.  This suggests an enrichment 
of the 46 kDa protein. What is also interesting is that we observed a 46 kDa species in 
our co-ip experiments that was exclusive to eIF3f in its association.  While it’s unclear 
if the 46 kDa protein we observed in the co-IP experiments is the same as the 
endogenous protein we found in the polysome preps, there are some indicators that the 
46 kDa protein is at least a similar protein to the endogenously expressed ERα46.  The 
antibody used (HC-20) is a polyclonal antibody specific to the C-terminus. The protein 
levels of the 46 kDa species also changed significantly with estradiol treatment, and 
are still present in samples treated with the proteasome inhibitor MG132 (data not 
shown). This suggests that it is not a proteasome-generated ERα fragment, but could be 
a product of protease digestion within the cell, which is why we suggest that it is a 
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truncated form of ERα, possibly generated by proteolytic cleavage and is very similar 
in nature to the naturally occurring ERα46 isoform.   
 ERα46 has been described as capable of binding EREs, but rather than 
recruiting the typical coactivating proteins, it recruits corepressors (54, 86). If ERα46 
antagonizes transcriptional activation of full-length ERα, binding of eIF3f with ERα46 
could prevent ERα46 from antagonizing full-length ERα.  This could explain how 
eIF3f knockdown resulted in decreased ERα transactivation because there was more 
ERα46 available to antagonize full-length ERα.  
 A model for how we envision ERα-eIF3f interaction is that absent estradiol, 
eIF3f can interact with both full-length ERα, and ERα46, but may have a preferential 
affinity for ERα46.  Upon ligand binding, ERα is known to associate more tightly with 
DNA (87).  Our data suggests that DNA-bound ERα, does not interact with eIF3f as 
seen in both the BiFC experiment as well as in the CHO A03 cells in which no co-
localization was seen in the presence of estradiol.  ERα46-eIF3f interaction may be 
more important for determining translation rates of specific estradiol-target genes.  
This could be accomplished through two mechanisms: eIF3f could help to modulate 
translation of estrogen-target genes, as has been the suggested function of non-core 
subunits of the eIF3 complex (22, 23) or, ERα46-eIF3f interaction, independent of 
mRNA binding, could alter the ability of mitogens such as estradiol to activate 
translation at the step of 4E-BP1, where eIF3f is known to mediate the interaction 
between S6K1 under basal conditions.      
 In order to confirm this model, it would be helpful to know if eIF3f interacts 
with ERα when ERα is bound to DNA.  This could be answered by performing ChIP 
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assays.  Another question would be if eIF3f prefers to interact with full-length ERα or 
ERα46.  The ability for estradiol to impact the rate of translation in a transcript-specific 
manner was recently demonstrated by Bronson et al (88).  They found that the initial 
translation state is already high for estrogen up-regulated transcripts before estradiol 
treatment and vice versa for estrogen down-regulated transcripts.  Another question is 
whether or not estradiol is capable of influencing global translation rates.  Contrary to 
our findings, Bronson et al did not observe a change in polysome profile of estradiol-
treated MCF-7 cells.  This difference in observation could be for a couple of reasons.  
First, Bronson et al only looked at 1 hour estradiol treatment.  We observed a decrease 
in the magnitude and number of polysomes at 20 minutes, which is consistent with 
what is known about activation of the cell cycle when cells shift from cap-dependent 
translation to cap-independent translation (66). We also looked at later time points of 
both 4 and 24 hours.  Our results suggest that any impact that estradiol may have on 
global translation rates is going to be either early (cessation of cap-dependent 
translation), or later than 4 hours, which may or may not be a primary action of 
estradiol.  With estradiol as a known mitogen, it is reasonable to try to relate the role of 
estradiol to translation given that translation is strongly regulated when progressing 
through the cell cycle. Changes in translation due to estradiol could also help to 
account for some of the rapid physiological changes known to occur at early time-
points of estradiol treatment (89-91).    
 In conclusion, we have identified eIF3f as an interacting partner of ERα.  We 
have found evidence that eIF3f knockdown can change the solubility and possibly the 
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location of ERα within the cell.  These changes may play a role in affecting the rate of 
translation of various transcripts within the cell.   
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Tables and Figures 
 
 
Table 2.1. Clones identified in yeast two-hybrid screen using amino acids 420-534 
of ERα . 
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Figure 2.1. Mammalian two-hybrid assay.  CHO cells were transfected with the 
respective constructs and treated with 10 nM estradiol for 24 h.  After estradiol 
treatment, cells were harvested and luciferase activity measured.  
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Figure 2.2. GST pull-down assay.  A) Full length eIF3f was radio-labeled with S35 
methionine using an in vitro TNT kit (Promega) and pulled down using the DEF 
domains of ERα in the presence and absence of 10 nM estradiol. B) Amino acids 1-198  
and 199-360 of eIF3f were similarly pulled down with the DEF domains of ERα in the 
presence or absence of 10 nM estradiol or 1 uM of the anti-estrogen ICI-182780.   
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Figure 2.3. Co-immunoprecipitation of ERα in HEK-293T cells.  A) Constructs 
were transiently expressed and treated with ligand for 15 minutes before cells were 
lysed and the lysate was subjected to M2-antibody coated agarose beads for 4 hours. 
Beads were washed and eluted with the subsequent eluent resolved and probed. B) 
Endogenous co-immunoprecipitation of eIF3f and ERα.  MCF-7 cells were lysed and 
the resultant lysate was subjected to ERα-coated agarose beads. Beads were washed 
and eluted with the eluant resolved and probed for eIF3f. 
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Figure 2.4. Immunostaining of eIF3f A) MCF-7 cells were stained with eIF3f 
primary antibody overnight, followed by Alexa Fluor 568 following fixation and 
mounted in Hard Set containing DAPI. Images were taken on a Zeiss microscope at a 
magnification of 20x. B) CHO A03 cells transiently expressing eIF3f and GFP-lac-
ERα with and without 10 nM E2 treatment. Images were taken on an Olympus 
microscope at 100x in several Z-stack plains. Images were then processed using 
deconvolution software.   
 54 
 
 
 
 Figure 2.5. Bi-molecular Fluorescence Complementation with eIF3f and ERα . A) 
pVC155-eIF3f and pVN173-ERα were transiently expressed in CHO cells along with 
p-ECFP-NLS  to help delineate the nucleus as well as serve as an expression control. 
24 hours following transient transfections, cells were treated with estradiol or vehicle 
for 1 hour prior to being fixed and mounted. B) pVC155-ERα and pVN173-ERα were 
transiently expressed for 24 hours prior to 6 hours of ICI or vehicle treatment. Cells 
were then fixed and mounted.  
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Figure 2.6. Sequential protein extraction from MCF-7 cells. MCF-7 cells were 
treated with indicated siRNA for 24 hours prior to 10 nM estradiol treatment. Cells 
were then harvested and whole cell extracts made.  The insoluble portion was then 
digested for 30 minutes with DNAse.  The remaining insoluble material was then 
subjected to 2.0 M NaCl to solubilize any remaining proteins.  The experiment was 
also performed in the presence of the proteasome inhibitor MG132.    
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Figure 2.7. eIF3f was knocked down in MCF-7 cells with siRNA. A) RNA was 
harvested after 2 and 24 hours of estradiol treatment and measured via quantitative 
PCR.  Knockdown of the protein was confirmed via Western Blot with Lamin A/C 
used as a loading control. B & C) Known up-regulated estradiol-target genes pS2, 
GREB-1, CA-12, c-Myc and TGFb3 were measured following eIF3f knockdown and 
estradiol treatment.  
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Figure 2.8. Polysome profiling and fractionation. A) MCF-7 cell lysates were 
separated on a sucrose density gradient and protein measured via the relative 
absorbance at 254 nm. B) Collected fractions were immuno-blotted for ERα and eIF3f. 
C) MCF-7 cells were treated for the indicated times and the polysome profiles are 
compared based on 254 nm absorbance.  
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Figure 2.9.  Differential regulation of translation by estradiol. Translation rates of 
known estradiol-regulated mRNAs change relative to their mRNA concentrations with 
estradiol treatment. Estradiol regulation of several known estrogen-regulated mRNAs 
are induced in MCF-7 cells as expected. Polysome association of the mRNA changes 
with estradiol treatment. The relative change in polysome association with respect to 
the steady-state mRNA level is represented in the Δ translation rate.   
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Figure 2.10.  Differential regulation of translation by estradiol. Changes in the 
mRNA transcription and translation of select cell-cycle genes and ESR1, the gene 
encoding ERα.  
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CHAPTER 3 
ESTRADIOL REGULATION OF THE NEGATIVE REGULATOR OF 
RECEPTOR TYROSINE KINASE LEUCINE RICH REPEAT AND IG DOMAIN 
PROTEIN 1 (LRIG1)  
 
Abstract 
We identify leucine-rich repeats and immunoglobulin-like domains protein 1 
(LRIG1) as an estradiol-regulated gene.  LRIG1 is a negative regulator of Receptor 
Tyrosine Kinase (RTK) signaling.  Up-regulation of LRIG1 mRNA and protein is 
mediated by the estrogen receptor-α (ERα) and we identified the regions of the LRIG1 
gene to which ER binds. LRIG1 regulation by estradiol helps to explain how tumors 
typically utilize either estradiol or growth factor pathways, but rarely both, as 
mitogenic stimuli.  Increased LRIG1, in response to estradiol, results in decreased 
signaling through RTK pathways.  The impact of LRIG1 regulation by estradiol is cell-
type specific.  LRIG1 protein levels are important for both the growth of cells as well 
as colony formation and invasiveness of ERα-positive and HER2-positive BT-474 and 
ERα positive and HER2-negative MCF-7 breast cancer cell lines.  LRIG1 regulation 
by estradiol may be important for breast cancer etiology and phenotypic properties by 
influencing signaling pathways such as the AKT and MAPK pathways, which help to 
determine the breast tumor subtype as well as responsiveness to cancer treatments.  
 
Introduction 
ER, PR and HER2 status has become the most discerning assay for predicting 
the response of breast tumors to treatment. These markers have proven helpful because 
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they are known to play central roles in regulating gene expression within the cell.  As a 
master regulator of transcription, ER can impact the transcription and subsequent 
expression of many proteins that ultimately determine the growth and invasiveness of a 
tumor. While over two-thirds of all breast tumors are ER positive, only 25-30% are 
HER2 positive (1).  Moreover, there is an inverse correlation between ERα and HER2 
expression. ER positive tumors are typically HER2 negative and vice versa. As ER 
positive tumors tend to dependent upon estrogens for their growth and maintenance, 
they typically respond well to endocrine therapies such as Tamoxifen, which acts as a 
selective modulator of estrogen receptor action, or the aromatase inhibitor Letrozole, 
which blocks the production of estrogens.  Typically, ER positive tumors that respond 
to endocrine therapies tend to be less aggressive, more differentiated and associated 
with a better clinical outcome (2). On the other hand, tumors that express HER2 
typically do not respond to endocrine therapy and are less differentiated and more 
aggressive.  
 While determining the ER, PR and HER2 status is still invaluable in 
determining course of treatment, the interest in better predicting the responsiveness of 
a tumor and the increased feasibility of studying whole genome expression of tumors 
have led to a more extensive and comprehensive classification of tumors. Several 
groups have applied gene expression profiling to large cohorts of breast tumors in 
order to classify tumors into different subtypes (3-6).   Among the various subtype 
groupings, the most commonly recognized subtypes include: normal-like breast, basal-
like, HER2 positive, luminal A and luminal B. Among these subtypes, ER, PR and 
HER2 over-expression typically segregate into different groups. The majority of 
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tumors fall within the luminal subtype. These tumors tend to be the less aggressive 
tumors, and, not coincidentally, are largely ER and/or PR positive, HER2 negative and 
generally respond well to hormone therapy. The luminal subtype is further divided into 
luminal A, which tend to have higher ER and PR expression, and luminal B, which 
tend to be slightly more aggressive and usually express some low level of HER2 and 
other growth factor receptors.  The subtype consisting of HER2 over-expressing 
tumors tend to be more aggressive and less likely to respond to hormone therapy as 
their growth is more dependent upon growth factors than estrogens (7).  These tumors 
often show good response to the HER2 targeted antibody, Herceptin.  
  In attempt to better understand the effects of estradiol in cancer, several 
groups have turned to microarray profiling of breast cancer cell lines.  Among these 
first forays into gene expression profiling of estrogen-target genes, our group examined 
both osteosarcoma U20S cells and the breast cancer cell line MCF7 (8, 9).  Among the 
many newly identified estrogen-target genes, we identified LRIG1, a negative 
regulator of receptor tyrosine kinase (RTK) signaling as being up-regulated by 
estradiol.  Subsequently, other groups have also found LRIG1 as being an estrogen-
regulated gene in several breast cancer cell lines, and also in a xenograft model (10).  
LRIG1 was also among a handful of genes identified to comprise a novel low-grade 
molecular signature in ER positive tumors (11). 
LRIG1 is a cell-surface integral membrane protein, so named for its 15 leucine-
rich repeats and three immunoglobulin domains.   Deletion of LRIG1 in mice results in 
a psoriasiform epidermal hyperplasia, a condition in which the role of the EGFR 
pathway has been implicated (12). More recently, LRIG1 expression was proposed to 
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define a distinct group of multipotent stem cells in the epidermis (13). LRIG1 has been 
characterized as a negative regulator of RTK signaling and has been shown to directly 
interact with several RTK proteins including all four members of the ErbB family (14-
20).  Decreased LRIG1 expression was found in breast tumors that displayed elevated 
levels of HER2 expression (19). Additionally, LRIG1 has been shown to interact with 
Met receptor and the Ret receptor in neuronal cells(17, 18).  Binding of LRIG1 with 
RTK family members has been shown to coincide with increased ubiquitylation and 
subsequent degradation of RTK target proteins.  Although it is not entirely clear how 
LRIG1 aids in the ubiquitylation of RTK proteins, a role for the E3 ligase c-Cbl has 
been demonstrated (14). Additionally, LRIG1 is reported to inhibit RTK signaling 
independent of its role in degradation of ErbB family members.  This ubiquitin-
independent role is most strongly evidenced through its ability to effectively reduce 
EGFR signaling of the oncogenic mutant, and degradation-resistant, EGFRvIII variant 
(20).  
Here we further characterize the regulation of LRIG1 by estradiol. We identify 
the regions of the LRIG1 promoter to which ER binds and demonstrate the ability of 
estradiol to increase LRIG1 mRNA and protein levels. This increase in LRIG1 protein 
levels result in diminished RTK signaling as evidenced by decreased phosphorylation 
of RTK family members and their downstream signaling components and target genes.  
Also, we demonstrate that this decrease in RTK signaling due to increased LRIG1 
expression results in decreased invasion of breast cancer cells.  LRIG1 regulation by 
estradiol helps to explain, in part, the observation that ER positive tumors tend to be 
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less invasive and aggressive compared to those tumors in which RTK signaling is more 
active.  
 
Materials and Methods 
Cell culture and experimental treatments   
MCF-7 cells were maintained in minimal essential medium (MEM; Sigma 
Chemical Co.) supplemented with 5% calf serum (HyClone), 100 µg/mL of 
penicillin/streptomycin (Invitrogen), and 25 µg/mL of gentamicin (Invitrogen). BT-474 
cells were maintained in DMEM (DMEM; Sigma Chemical Co.)  and antibiotics 
supplemented with 10% fetal bovine serum (Atlanta Biologicals) and bovine insulin (8 
ng/mL; Sigma).  Prior to experiments, cell were grown in phenol-free MEM or 
DMEM, supplemented with 5 or 10% charcoal dextran-treated calf (CD-CS) or fetal 
bovine serum (CD-FBS) , respectively, for a minimum of two days.  
 
Western blot analysis   
Whole-cell extracts were prepared by harvesting cells directly into 2× SDS-
PAGE sample buffer containing 125 mM Tris pH 6.8, 20% glycerol, 4% SDS, 0.02 
mg/ml bromophenol blue and 5% β-mercaptoethanol.  Protein (25-100 µg)was 
separated on 4-20% SDS-PAGE gels (Bio-Rad) and transferred to nitrocellulose 
membranes.  Antibodies were purchased from Cell Signaling Technology for EGFR 
(catalog no. 2646), phospho-EGFR Tyr1045 (catalog no. 2237) HER2 (catalog no.  
3250), phosph-HER2 Tyr877 (catalog no. 2241) Her3 (catalog no. 4754), phospho 
Her3 Tyr1289 (catalog no. 4791) Her4 (catalog no. 4795), p44/42 (MAPK) (catalog 
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no. 9102), phospho-p44/42 (pMAPK) (catalog no. 9101), Akt (catalog no. 9272), 
phospho Akt Tyr308 (catalog no. 2965), phospho-Akt Ser473 (catalog no. 4060). 
LRIG1 antibody (Abcam ab36707) was purchased from Abcam and β-actin (Clone 
AC-74 Catalog No. A2228) was purchased from Sigma-Aldrich.  Secondary antibodies 
were purchased from Jackson Laboratories. All antibodies were used per 
manufacturer’s instructions.  Detection was performed using SuperSignal West Pico or 
Femto Chemiluminescent Substrate. 
 
RNA isolation, reverse transcription, and real-time PCR  
Cell RNA was prepared using TRIzol reagent (Invitrogen) according to the 
manufacturer’s recommendations. RNA samples were reverse-transcribed in a total 
volume of 20 µl using 200 units of reverse transcriptase, 50 pmol of random hexamer, 
and 1 mM of deoxynucleotide triphosphates (New England Biolabs). The resulting 
cDNA was then diluted to a volume of 500 µL with nuclease-free water. Real-time 
PCR was performed on an ABI Prism 7900HT instrument using SYBR Green PCR 
Master Mix (Applied Biosystems) according to the manufacturer’s recommendations. 
Briefly, each PCR contained 1× master mix, 4 µl of the diluted cDNA reaction, and 50 
nM of forward and reverse primers designed to yield 80- to 125-bp amplicons. PCR 
was carried out through 40 cycles (95°C for 15 s, 60°C for 1 min) following an initial 
10-min incubation at 95°C. Relative expression levels were calculated as described 
previously, using acidic ribosomal protein 36B4 mRNA as an internal control (21). 
Primers for LRIG1 ChIP were as follows: P1 (forward, 
GCCTGAAGTCTCCTGCCATA; reverse, ACCAGGCCAAGGTAGCTTTT), P2 
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(forward, TAACTGATGGCTGCTGTTGC; reverse, 
TTTGCCTTGCCAGAATTACC), P3 (forward, GCACCTGCACAAACTCGTCA; 
reverse, GCCTACCATTTGTCTCATGCC), control (forward, 
GACACAGCACCTCCTGAACA; reverse, AGAGCACCTCCCTCTTCACA), P4 
(forward, CTGGGGAATTTTGGCAGAT; reverse, 
GTTGGTTGACACAGCCCAGT), P5 (forward, CTAGGCTTCCCTCTCCAAGG; 
reverse, ATGGGTGAGAGTTGGACTGG), P6 (forward, 
CAGGGAGAGGTCAGAGCAAC; reverse, CATCTTTTCAGGGAGGGTGA) For 
LRIG1 steady state mRNA measurements: forward, ACGGTGAGCCTGGCCTTAT; 
reverse, GTCAGGTCACTTTCGGGCA. 
 
Small interfering RNA (siRNA) studies  
siRNA duplexes targeting ERα (forward, 
UCAUCGCAUUCCUUGCAAAdTdT; reverse, 
UUUGCAAGGAAUGCGAUGAdTdT), or GL3 luciferase  (no. D-001400-01); ON-
TARGETplus Non-targeting Pool (no. D-001810-10-20), or ON-TARGETplus 
SMARTpool (no. L-013940-00-0020, Human LRIG1, NM_015541) were obtained 
from Dharmacon and transfected into cells at a final concentration of 20-50 nM using 
DharmaFECT transfection reagent according to the manufacturer’s recommendations. 
 
Transient protein expression studies  
LRIG1 expression in MCF-7 and BT-474 cells was performed using a non-
recombinant adenovirus DNA transfer procedure (22, 23).  Briefly, polylysine-coupled 
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adenovirus was prepared and then mixed with plasmid DNA. The plasmid DNA binds 
to the adenovirus particle through the polylysine chains. The adenovirus-plasmid 
particles were then added to cells, and the plasmid DNA was carried into the cells 
along with the adenovirus. MCF-7 or BT-474 cells were plated in 100-mm dishes (3 × 
106 cells/dish) in their respective medium (see above). 24 h after plating, the medium 
was removed and replaced with serum-free medium to prepare the cells for the 
adenovirus infection. LRIG1 expression plasmid (8.0 µg/dish) was mixed with 
adenovirus (virus to cell ratio, 250:1) and the resulting mixture was added to the 
dishes. Four hours post-infection, CD-CS or CD-FBS was added to the dishes to give a 
final concentration of 5% CD-FBS. After 24 h, the medium was removed and the cells 
were seeded in 6-well plates at 2.5×105 cells per well. 
 
Invasion Assays 
Matrigel invasion assays were carried out using pre-coated filters (8µm pore 
size, Matrigel 100µg/cm2). 2×104 cells in medium containing 2% calf serum were 
seeded into the upper chamber and 700µl MEM containing 10% calf serum was used 
to create a serum gradient in the bottom chamber. Following incubation for the 
indicated times at 37°C, cells were fixed and stained with Wright-Giemsa (Sigma-
Aldrich). Non-invaded cells on the upper surface of the filter were removed with a 
cotton swab, and invasiveness quantified by counting stained cells. Invasion assays 
were performed in triplicate and the average (± 1 SD) cell count reported. 
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Cell Proliferation Assays 
The WST-1 reagent was used to quantify cell viability by colorimetry based on 
the metabolic cleavage of the tetrazolium salt. The WST-1 assay was performed 
according to the manufacturer’s protocol (Roche, Basel, Switzerland) and absorbance 
was measured at 450nm with reference to 650nm using a BioRad 680 Microplate 
Reader. Assays were performed in triplicate and average (±1 SD) optical density 
reported. 
 
Results 
LRIG1 expression is up-regulated by estradiol in MCF7 and BT474 cell lines 
 We first looked at estradiol regulation of LRIG1 mRNA in MCF7 breast cancer 
cells.  Using quantitative PCR, we observed in time-course studies an up-regulation of 
LRIG1 mRNA as soon as four hours after estradiol treatment and mRNA remained 
elevated at both 6 and 24 hours (figure 3.1, panel A).  In order to further determine if 
LRIG1 is regulated by estradiol through ER, we knocked down ERα using siRNA.  
Upon ERα knockdown followed by 4 hours of estradiol treatment, LRIG1 mRNA was 
not increased compared to siControl (figure 3.1, panel B).   Additionally, treatment 
with the anti-estrogen ICI failed to induce LRIG1 mRNA and suppressed the 
stimulation by estradiol (data not shown), further demonstrating the need for an 
agonist-bound ERα receptor for LRIG1 up-regulation.  Together these data 
demonstrates that estradiol regulates LRIG1 mRNA induction through ER. 
Up-regulation of LRIG1 mRNA also resulted in a concomitant increase in 
LRIG1 protein levels (figure 3.1, panel C), an observation confirmed not only in 
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MCF7 cells but also in two other ER-positive breast cancer cell lines: ZR75 and 
BT474.  To better understand the kinetics of LRIG induction, we performed an 
estradiol time course treatment and monitored LRIG protein levels by immunoblot.  
LRIG1 protein levels increased as early as 2 h and were elevated up to 12 h and 
decreased at 24 h.  This regulation was observed in all three breast cancer cell lines 
tested. 
 
LRIG1 contains several intronic ER binding sites 
As treatment of ER-positive breast cancer cells with estradiol resulted in 
increased LRIG1 mRNA and protein expression, we next sought to identify the regions 
of the LRIG1 promoter responsible for estradiol regulation.  Taking advantage of 
recently reported global mapping of ER binding sites in MCF7 cells using chromatin 
immunoprecipitation sequencing (ChIPseq) from three different groups (24-26), we 
compared reported ERα binding sites on the LRIG1 promoter region (figure 3.2).  
Published ERα binding data from Welborn et al is represented in figure 3.2. Within the 
LRIG1 gene locus, there are several peaks of ERα binding. To confirm regions of ER 
binding, we performed ChIP experiments on the five/six regions of the LRIG1 
promoter upon which the greatest ER binding was observed (figure 3.2B).  We were 
able to confirm significant ER binding to several of the regions examined after 45 
minutes of estradiol treatment.  As a negative control, we performed ChIP experiments 
to other internal regions of the LRIG1 promoter to which we did not anticipate ER 
binding. As expected, we did not observe ER binding in these regions within the 
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LRIG1 gene, clearly showing the specificity of ER binding to the aforementioned 
LRIG1 internal binding sites.  
 
Impact of LRIG1 over-expression on RTK signaling 
 Because LRIG1 is known to impact RTK signaling, we over-expressed LRIG1 
in cells via poly-lysine-coated adenovirus infection.  As shown in figure 3.3, we were 
able to successfully over-express LRIG1 in both MCF-7 and BT-474 breast cancer cell 
lines.  Upon LRIG1 over-expression, we observed two qualitatively different responses 
to LRIG1 in the two cell lines.   LRIG1 over-expression in MCF-7 cells did not appear 
to impact EGFR or HER2 total protein levels, while over-expression in BT-474 cells 
significantly decreased total EGFR and HER2 protein levels, which are very low.   
Interestingly, despite this difference between the two cell lines, LRIG1 over-expression 
decreased phospho-EGFR and phospho-HER2 in both breast cancer cell lines.  We 
then looked at the downstream RTK effectors, MAPK and AKT.  Our data suggest that 
LRIG1 over-expression impacted both the MAPK and AKT pathway, although the 
effect on the MAPK pathway was less pronounced.   LRIG1 impact on MAPK and 
AKT was only observed in BT-474 and not MCF-7 cells.  
 
Impact of LRIG1 knockdown on RTK signaling in the presence and absence of 
estradiol 
We next utilized siRNA directed at LRIG1 to evaluate differences in signaling 
of the RTK pathway in MCF-7 cells (figure 3.4).  Knockdown of LRIG1, followed by 
a time course of 5 nM Heregulin, was used to observe the impact of LRIG1 expression 
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on Heregulin signaling.  With LRIG1 knockdown, we observed a significant increase 
in HER2 phosphorylation but not EGFR phosphorylation.  We next looked to see what 
impact LRIG1 knockdown had on either MAPK or AKT signaling.  We did not 
observe a significant change in MAPK signaling (data not shown), but we did observe 
a significant difference in AKT signaling after 5 minutes of Heregulin treatment. 
LRIG1 knockdown resulted in a higher level of AKT phosphorylation after 5 minutes 
of Heregulin treatment.  This difference in phosphorylation did not persist as phospho-
AKT levels appeared comparable after 15 minutes of Heregulin treatment and 
remained comparable after 4 hours (240 minutes).   
We next performed the same experiment, but this time in the presence of 
estradiol.   In this experiment, our aim was to see what effect, if any, 24 hours of 
estradiol treatment had on RTK signaling with and without LRIG1 knockdown.  As 
expected, siRNA directed at LRIG1 significantly decreased the total LRIG1 protein, 
though LRIG1 levels were somewhat increased due to estradiol induction.  We 
observed the same difference in HER2 phosphorylation with and without LRIG1 
knockdown as observed in the non-estrogen treated samples above.  There was also no 
significant change in EGFR phosphorylation.  In the presence of estradiol, we did 
observe a significant difference in AKT activation.  We no longer observed the same 
punctuated increase after 5 minutes of Heregulin treatment with or without LRIG1 
knockdown.  But in those samples in which LRIG1 was knocked down, there appeared 
to  now be a sustained increase in AKT phosphorylation at all time points tested.  
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Increased LRIG1 expression impacts estradiol regulation of specific genes 
 In order to better understand the impact of elevated LRIG1 protein levels 
following Heregulin treatment, we again utilized lysine-coated adenovirus to over-
express LRIG1 (figure 3.5).  Following LRIG1 over-expression, we subjected cells to 
treatment with 5 nM Heregulin for four hours.  We then looked at target genes reported 
to be regulated in MCF-7 cells by both estradiol and Heregulin.  On all genes except 
FOS, we found that increased LRIG1 expression alone decreased their steady state 
mRNA levels (EGFR, HER2, MYC and PMAIP).  Heregulin treatment further lowered 
their steady state mRNA levels, greatly for EGFR and HER2, but minimally for MYC 
and PMAIP.  For FOS, LRIG1 over-expression increased FOS mRNA, but also 
decreased FOS mRNA following four hours of Heregulin treatment (Figure 3.5).  
 
Knockdown of LRIG1 increases invasion of BT-474 cells 
We next looked at the effect of LRIG1 knockdown on the invasiveness of BT-
474 cells in an invasion assay.  BT-474 cells were subjected to siRNA directed at 
LRIG1 before being seeded in Matrigel-coated plates.  A time course experiment was 
then performed, harvesting cells at 24, 48 and 72 hours.  Cells with knockdown of 
LRIG1-directed siRNA showed a significant increase in invasion .  This difference was 
evident as soon as 24 hours, and increased at both 48 and 72 hours.   
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Knockdown of LRIG1 increases estradiol-stimulated growth of BT474 but not MCF-7 
cells 
 We next looked at the functional impact of LRIG1 knockdown and subsequent 
estradiol or Heregulin treatment on the growth of MCF7 and BT474 cells. After 24 
hours of siRNA treatment, cells were treated with estradiol, Heregulin or both.  
Viability was then measured after 6 days of ligand treatment.  As shown in Figure 3.6, 
knockdown of LRIG1 resulted in an increase of growth over that of cells treated with 
non-targeting siRNA in MCF-7 cells.  This difference was not observed in BT-474 
cells in which LRIG1 knockdown did not appear to significantly change cell viability.  
In contrast, BT-474 cells did increase in growth with LRIG1 knockdown, but only 
when also treated with 10 nM estradiol.   Heregulin treatment did not appear to 
increase growth in either cell line, with or without LRIG1 knockdown.  Interestingly, 
treatment with both 10 nM estradiol and 5 nM Heregulin resulted in a decrease in 
viability of both cell lines, but was more pronounced in MCF-7 cells.   This 
phenomena has been previously reported in MCF-7 cells that were also treated with 
both Heregulin and estradiol (27).   
 
Impact of LRIG1 knockdown on Colony Formation  
 We next looked at the impact of LRIG1 knockdown and subsequent ligand 
treatment in colony formation assays.  In this assay, we first looked at the impact of 
LRIG1 on the number of colonies formed, when subjected to either vehicle, 10 nM 
estradiol, 5 nM Heregulin or both Heregulin and estradiol.  When we examined BT-
474 cells, we found that LRIG1 knockdown increased the number of colonies in every 
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different ligand treatment (figure 3.7A).  We also wanted to see if this increase in the 
number of colonies was also associated with increases in the colony size (figure 3.7B).  
To do this, we utilized ImageJ software to count and measure the size of the colonies.  
We found that, compared to vehicle treated cells, the estrogen treated cell colonies 
were increased in number, but were smaller in size.  Treatment with Heregulin resulted 
in an increase in both the size and number of colonies compared to vehicle.  Treatment 
with both estradiol and Heregulin resulted in a specific increase in larger colonies.  
This difference in colony size was statistically compared using a 2-way ANOVA 
analysis.  The analysis demonstrated that the increase in colony number due to ligand 
treatment was significant when compared to each of the differences as a result from 
ligand treatment.   This is compared to the difference in colony size in which the only 
statistically significant difference was seen in the colonies grown in both estradiol and 
Heregulin.   
 These differences in colony number and size were also found to be cell-type 
specific, as MCF-7 cells responded differently to ligand.  LRIG1 knockdown did not 
cause a uniform increase in the number of colonies formed as it did in BT-474 cells, 
but rather showed a significant increase in colony number only with colonies grown in 
5 nM Heregulin (Figure 3.8A).  Consistent with the growth assays, we found that the 
trend in colony number decreased in cells subjected to both estradiol and Heregulin, 
compared to the increase in colony number with either ligand alone.  
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LRIG1 expression is higher in less-aggressive tumors and more frequently deleted in 
more aggressive tumors  
 With the various reported observations of estradiol regulation of LRIG1 in both 
expression profiling of primary breast tumors and in breast cancer cell lines, we 
wanted to investigate LRIG1 expression in ER positive tumors. Using data found in 
Oncomine from four different large clinical data sets in which the tumor subtype and 
nuclear hormone receptor status were determined, we compared LRIG1 mRNA 
expression in luminal A and luminal B tumors. As seen in Figure 3.9A, in a total of 
238 primary tumors, LRIG1 mRNA expression was found to be significantly higher in 
luminal A tumors compared to luminal B tumors (p<0.0001). We also looked at 
LRIG1 expression in luminal A and B tumors that had been treated with the Selective 
Estrogen Receptor Modulator (SERM) Tamoxifen.  In a total of 66 primary tumors, 
LRIG1 expression was significantly greater in luminal A tumors compared to luminal 
B tumors.  Next, we investigated LRIG1 expression in three primary breast tumor 
microarray data sets in which clinical data was available. Low levels of LRIG1 mRNA 
expression were significantly associated with the onset of metastasis. 
 After determining LRIG1 mRNA expression in ER-positive tumors, we next 
looked to determine if there were differences in genome deletion or amplification of 
the LRIG1 gene locus (3p14.1) in various breast cancer subtypes.  By taking advantage 
of array Comparative Genomic Hybridization (aCGH) data from four different data 
sets, totaling 172 primary tumors (28), we observed LRIG1 to be more often deleted 
than amplified.  LRIG1 deletion was more frequent in more aggressive tumor subtypes 
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such as those containing HER2 amplifications and Basal-like (triple negative) tumors, 
and least prevalent in the least aggressive luminal A subtype (Figure 3.9). 
 Together, these data demonstrate that LRIG1 expression is higher in ER-
positive tumors that tend to be the least aggressive.  Additionally, the region of 
chromosome 3 containing the LRIG1 gene locus is found to be deleted more frequently 
in aggressive tumor subtypes such as HER2 amplified and basal-like tumors.  
 
Discussion 
 Recent studies have utilized gene expression microarray analysis to distinguish 
between two groups of ERα positive tumors (3-5), the luminal A subtype, which is 
characterized by high ERα levels, better response to endocrine therapy and typically 
has a more favorable prognosis; and the luminal B subtype, which typically is more 
aggressive, has a higher proliferation rate, elevated HER2 expression, and is usually 
less responsive to endocrine therapy.  In this study, we utilize the luminal A-like cell 
line MCF-7 and luminal B-like cell line BT-474 as models to investigate the impact of 
LRIG1 levels on RTK signaling, gene regulation and cell properties such as 
proliferation, colony formation and invasiveness.  As both cell lines express ERα, 
albeit it at different levels, we found both cell lines to show increased LRIG1 
expression in response to estradiol.  A recent study investigated deregulation of the 
PI3K (AKT) in ER positive tumors (29). They found that increased PI3K activity 
negatively correlated with ER expression levels and that PI3K activity was higher in 
the luminal B breast cancer subtype.  Another group found that endocrine resistance in 
ER positive tumors is promoted by increased PI3K activity (30). Their observations are 
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consistent with our results here, where we demonstrate that LRIG1 regulation by 
estradiol reduces AKT signaling and that this reduction is more pronounced in the 
luminal B-like BT-474 breast cancer cell line.    
As it is standard practice to deprive cells of any estrogens prior to estradiol 
treatment, LRIG1 induction by estradiol was performed in cells that were either in 
serum-free media for 24 hours or grown for at least 48 hours in charcoal-dextran 
stripped serum prior to treatment.  We found that removal of serum alone greatly 
reduced the levels of LRIG1 in MCF-7 cells (data not shown).  In addition to the 
estradiol present in bovine serum, it is likely that other factors also regulate LRIG1 
protein levels including growth factor signaling as it has been reported that LRIG1 
mRNA and protein levels decrease in response to increased HER2 expression in MCF-
7 cells and that Heregulin treatment reduces LRIG1 expression after 24 hours (19).  
Additionally, the EGF ligand has been reported to increase LRIG1 mRNA and protein, 
in HeLa cells (14).   Regulation by many factors, including estradiol, is consistent with 
the known role of LRIG1, namely, in response to the removal of growth factors, cells 
will increase their growth factor-sensitivity by decreasing the amount of a negative 
regulator.  Interestingly, in the presence of complete serum, estradiol was still capable 
of significantly increasing LRIG1 protein (data not shown).  
 In further investigating estradiol regulation of LRIG1, we found several 
locations within the LRIG1 gene locus to which ERα binds in an estradiol-dependent 
manner.  Interestingly, all of these ER-binding sites were located in the intronic regions 
of LRIG1.  No ER-binding sites were found either in the promoter or downstream 
region of the LRIG1 gene.   While intronic binding of transcription factors is not 
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uncommon, it is interesting that we did not observe any ERα bound near the 
transcriptional start site.  Of note, in the data reported by Welboren et al, there was an 
estradiol-dependent increase in polymerase II binding along the entire LRIG1 gene 
locus (26).  Knockdown of ERα abrogated LRIG1 regulation by estradiol (Figure 
3.1B), further demonstrating the need of ERα for LRIG1 induction. Estradiol-
dependent binding of ERα occurs on several intronic LRIG1 sites and is concomitant 
with increased polymerase II binding in response to estradiol.   
 Over-expression of LRIG1 resulted in changes in RTK signaling in a cell-type 
and pathway specific manner.  While increased LRIG1 expression in MCF-7 cells did 
not appear to significantly impact the protein levels of either EGFR or HER2, it did 
appear to decrease the activation by phosphorylation of both proteins in response to 
Heregulin.  By contrast, in BT-474 cells, LRIG1 over-expression significantly 
decreased the protein levels of both EGFR and HER2.  We also observed a decrease in 
the levels of phospho-EGFR and phospho-HER2 with LRIG1 over-expression.  It is 
unclear from our experiments if this is a direct result of LRIG1 over-expression, or if 
this is the result of the reduction in total EGFR and HER2 protein.   
BT-474 cells are more reliant on RTK signaling for their growth and 
maintenance compared to MCF-7 cells.  Several of the RTK protein family members 
are expressed at much higher levels in BT-474 cells than MCF-7 cells. As such, it is 
possible that the pathways are in a greater state of flux and are more malleable, 
allowing for a greater range of response to growth factors in BT-474 cells. Of 
particular note, the ability of LRIG1 over-expression to significantly reduce the 
amplified HER2 protein in BT-474 cells was impressive when considering the high 
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expression levels of HER2.  LRIG1 over-expression also appeared to impact 
phosphorylation of MAPK.  This is in contrast to the reports of Miller et al, where no 
changes in MAPK signaling were observed, while they did observe changes in AKT 
signaling (19).  The difference could be in the cell lines tested as we observed 
differences in MAPK signaling by over-expressing LRIG1 in MCF-7 and BT-474 cells 
while Miller et al over-expressed LRIG1 in the ER-negative MD-MB-453 and SKBR3 
breast cancer cells.   
 Both knockdown of LRIG1 and pre-treatment with estradiol had an observable 
impact on phosphorylation of AKT in response to Heregulin.  Most strikingly, 
treatment with estradiol appeared to dramatically reduce the initial spike in phospho-
AKT at 5 minutes of Heregulin treatment. (Figure 3.4, compare p-AKT 308 in top 
panel to bottom panel)  Knockdown of LRIG1 and estradiol treatment resulted in a 
higher overall phospho-AKT signal over the time-course of Heregulin treatment 
compared to vehicle treated (Figure 3.4, bottom panel, compare siNT to siLRIG).   
The changes we observed upon knockdown of LRIG1 with respect to phospho-
HER2 and phospho-EGFR did not appear to be as pronounced when compared to the 
changes induced by over-expression of LRIG1.  A possible explanation for this 
difference is that LRIG1 levels are significantly lower in cells that have spent time in 
stripped serum, or serum free conditions (data not shown).  Further depleting cells of 
LRIG1 by siRNA when LRIG1 levels are already very low may result in minimal 
impact on EGFR and HER2 protein levels.  From an economic standpoint, it makes 
sense modulate a single negative regulator of many RTK proteins in response to the 
removal of growth factors instead of modulating several of the RTK proteins. 
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Changes in phospho-AKT are likely to result in differences in AKT-target gene 
transcription.  To this end, we over-expressed LRIG1 to partially mimic the increased 
LRIG1 expression that occurs with estradiol treatment.  We looked at some select 
genes reported to be regulated by both Heregulin and estradiol in MCF-7 cells. It has 
been reported that not many genes within MCF-7 cells demonstrate both estradiol and 
Heregulin treatment. A comparison with previously reported estrogen-regulated gene 
expression data revealed that only 12 common genes were identified between the 333 
Heregulin-regulated (3.6%) and 239 E2-regulated (5.0%) gene groups (31).  While 
only looking at a few genes, LRIG1 over-expression substantially altered the mRNA 
levels of EGFR, HER2, and the FOS gene.  As our biochemical data suggested that the 
impact of modulating LRIG1 protein level is most influential on the AKT pathway, 
and that the impact of LRIG1 on the pathway appears to alter the intensity and duration 
of the signal, it might be of great interest to look at the impact of LRIG1 over-
expression or knockdown on global gene expression via microarray analysis.  
We also looked at the functional impact of LRIG1 knockdown in BT-474 cells.  
We observed a significant increase in invasion of BT-474 cells upon LRIG1 
knockdown.  This is consistent with the role of LRIG1 as a negative regulator of RTK 
signaling, as the removal of a negative regulator would increase invasion, a process 
known to be regulated by RTK signaling (32).  Similarly, we found that LRIG1 
knockdown resulted in a cell-type specific estradiol-response in our viability assay.  
BT-474 cells displayed increased growth upon LRIG1 knockdown and estradiol 
treatment.  This was not the case in MCF-7 cells where LRIG1 knockdown did not 
impact estradiol-mediated growth, but rather did have a significant impact on the 
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vehicle treated sample.  In both cell lines, the combination of estradiol and Heregulin 
treatment significantly decreased cell growth.  While somewhat surprising, this was 
previously reported by St-Laurent et al (27). Heregulin has also been reported to have a 
greater impact on differentiation than proliferation in MCF-7 cells (33).   
The increase in basal proliferation of vehicle treated MCF-7 cells likely 
occurred because LRIG1 knockdown enabled the mitogenic actions of RTK signaling 
to be more strongly transduced.  The reasons for the observed increase in estrogen-
mediated proliferation of the BT-474 cells may not be as straight forward.  One 
possible explanation comes in the reported function of the LRIG-1 homolog in 
Caenorhabditis elegans, SMA-10.  SMA-10 was found to be a positive regulator of 
bone morphogenic protein (BMP) signaling (34).  Along with SMA-10, LRIG1 was 
found to bind to both type I and type II BMP receptors.  BMP signaling has also been 
reported to antagonize the growth of prostate cancer cells through the interaction of 
Smad1 with activated Androgen Receptor (35). Knockdown of LRIG1 could be 
reducing BMP signaling, thereby allowing for increased proliferation.   
We also observed other differences in the ligand responsiveness between MCF-
7 and BT-474 cells upon LRIG1 knockdown in the colony formation assay.  
Knockdown of LRIG1 in BT-474 cells resulted in an increase in the number of 
colonies under basal (vehicle) conditions, as well as in response to both estradiol and 
Heregulin.  In the absence of LRIG1 knockdown, BT-474 cells demonstrated a modest 
increase in colony numbers for both estradiol and Heregulin treated cells.  The 
combination of estradiol and Heregulin appeared to be additive in terms of growth 
compared to basal (Figure 3.7, panel A).   
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This was not the case in LRIG1 knockdown cells where there was a significant 
increase in both the estradiol and Heregulin treated cells, yet no apparent additive 
effect upon addition of both ligands.  While this effect did not appear to be additive, 
the combination of the two ligands and LRIG1 knockdown did result in the largest 
increase of larger colonies compared to all the other treatments (Figure 3.7, panel B).  
This is in contrast to MCF-7 cells in which the combination of estradiol and Heregulin 
did not increase the number of larger colonies in combination following LRIG1 
knockdown.  Heregulin treatment and LRIG1 knockdown appeared to affect the 
greatest increase in larger colonies in addition to causing the greatest increase in 
colony numbers (Figure 3.8, panels A & B).   Estradiol treatment alone appeared to 
increase the number of colonies over basal conditions, while LRIG1 knock down did 
not appear to impact estradiol growth compared to that of Heregulin (Figure 3.8, panel 
A).  
The different responses to ligand between BT-474 and MCF-7 and cells in 
conjunction with LRIG1 knockdown may provide some insight into the differences 
between the luminal A and luminal B subtype as well as what may occur in endocrine 
resistant tumors.  LRIG1 knockdown impacted colony numbers for both estradiol- and 
Heregulin-treated BT-474 cells.  This suggests that LRIG1 levels are going to have a 
greater impact on the growth of luminal B subtype tumors compared to the luminal A 
subtype.  By extension, the impact of LRIG1 regulation by estradiol is more likely to 
influence luminal B-like tumors than luminal A in part because luminal B tumors rely 
more upon growth factor signaling.  Furthermore, the significant increase in colony 
size upon treatment with both estradiol and Heregulin upon LRIG1 knockdown is 
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consistent with the more aggressive phenotype of luminal B tumors.  This increase in 
size was not observed in MCF-7 cells where Heregulin alone had the biggest affect on 
colony size following LRIG1 knockdown.   
Our findings are consistent with LRIG1 expression that has been reported in the 
various breast tumor subtypes (Figure 3.9).  Luminal A subtype tumors tend to express 
higher LRIG1 levels than do luminal B tumors.  The data from the colony formation 
assay would suggest that lower LRIG1 levels would contribute to the aggressive 
phenotype of luminal B tumors.  Furthermore, patients who developed resistance to 
endocrine therapy demonstrated lower LRIG1 mRNA expression (Figure 3.9, panel A).  
This suggests that LRIG1 expression might affect the development of antiestrogen 
resistant tumors. Consistent with this idea, it has been shown in xenograft tumors 
grown from luminal A-like MCF-7 cells that Tamoxifen treatment results in a slight 
increase in EGFR and HER2 protein.  This increase becomes more pronounced in 
resistant tumors (36).  In the same xenograft model, using wild type MCF-7 cells and  
HER2-overexpressing MCF-7 cells, showed that, following estrogen depravation,  
tumors from both cell lines activated HER2 growth factor signaling and no longer 
relied upon estradiol for growth (37). This is consistent with the observation that 
LRIG1 expression is higher in individuals in whom no tumor recurrence was found 
relative to those in whom tumors did recur (Figure 3.9, panel C).  Together these data 
consistently suggest that LRIG1 expression is an important factor in the molecular 
decisions that help to determine endocrine resistance as well as tumor subtype.  
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Figures 
 
 
 
 
Figure 3.1. Estradiol up-regulates LRIG1 mRNA and LRIG1 protein through 
ERα.  A) LRIG1 mRNA is induced in a time-dependent manner by E2 in ERα-
expressing MCF-7 breast cancer cells. Cells were treated with 10 nM of E2 for 0 to 24 
h. RNA was isolated, reverse-transcribed, and cDNA measured by quantitative PCR 
using primers for LRIG1 and internal control 36B4 mRNA.  B) LRIG1 mRNA 
induction is ERα-dependent. MCF-7 cells were transfected with 5 nM of siControl or 5 
nM of siRNA against ERα for 72 h. Cells were then treated for 4 h with 0.1% ethanol 
or 10 nM of E2 prior to RNA isolation and qRT-PCR analysis.  C) LRIG1 protein 
levels is increased by E2 in a time-dependent manner in both luminal A- and luminal 
B-like breast cancer cells.  ERα-expressing MCF-7, ZR-75, and BT-474 cells were 
treated with 10 nM of E2 for 0 to 24 h and total cellular lysates were used for 
immunoblotting for LRIG1 and the internal control β-actin.  
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Figure 3.2.  ERα and RNA polymerase II are recruited to the LRIG1 genomic 
locus in vivo.  A) Whole-genome localization of ERα and RNAPII binding sites were 
mapped in MCF-7 cells treated with 10 nmol/L of E2 for 45 min using the ChIP-seq 
strategy (from Stunnenberg et al. (26)).  Density histograms for recovered, sequenced 
DNA fragments and validation primers sets are mapped to the LRIG1 genomic region 
in the UCSC Genome Browser (Hg18). B) E2-occupied ERα is recruited to multiple 
binding regions of the LRIG1 locus.  MCF-7 cells were treated for 45 min with control 
0.1% ethanol or 10 nM of E2, subjected to ERα ChIP, and immunoprecipitated DNA 
amplified using PCR primers as denoted above and recovered DNA represented as a 
percentage of the input. 
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Figure 3.3. LRIG1 over-expression decreases basal and activated growth factor 
signaling in a cell-type specific manor.  A and B) LRIG1 was over-expressed in 
MCF-7 and BT-474 cells by using lysine-coated adenovirus.  Cells were then treated 
with Heregulin (HRG) or vehicle from 0 to 240 minutes (4 h). LRIG1 over-expression 
resulted in no change to the EGFR, or HER2 protein levels in MCF-7 cells, compared 
to BT-474 cells in which EGFR and HER2 proteins were reduced.  Phospho-EGFR 
and phospho-HER2 levels appear to be reduced in both cell lines in response to 
Heregulin treatment. Phospho Akt levels were also reduced in BT-474 cells. Phospho-
MAPK levels were only minimally affected by LRIG1 overexpression.  
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Figure 3.4. Knock down of LRIG1 elicits changes in RTK phosphorylation 
downstream effectors. Knock down of LRIG1 in MCF-7 cells results in higher 
phosphorylation of HER2, EGFR, and AKT308.  Reduced LRIG1 levels in the 
presence of E2 changes the phosphorylation intensity and duration of pAKT308 
(compare top panel p-AKT308 to bottom). 
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Figure 3.5. LRIG1 over-expression has differential effects on Heregulin-regulated 
gene expression in BT-474 cells.  A) LRIG1 was over-expressed in BT-474 cells by 
using lysine-coated adenovirus.  Cells were then treated with Heregulin or vehicle for 0 
or 240 minutes (4 h) and mRNA harvested and analyzed by qRT-PCR. 
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Figure 3.6. LRIG1 knockdown increases invasiveness of BT-474 cells and 
stimulated viability of BT-474 but not MCF-7 cells.  A) Cells were treated with 
either siNT (non-targeting) or siLRIG1 for 24 hours before seeded in 96 well plates 
and grown for 6 days with either vehicle, 10nM E2, 5 nM HRG or both E2/HRG. In 
BT-474 cells, LRIG1 knockdown resulted in increased viability of 10 nM, E2 treated 
cells.  In MCF-7 cells, LRIG1 knockdown increased basal viability in both veh and E2 
treated cells.  In both cell types, 5 nM HRG resulted in reduced viability.  Treatment 
with both E2 and HRG had an additive effect in reducing viability, particularly in 
MCF-7 cells. 
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Figure 3.7. Knockdown of LRIG1 followed by co-treatment of BT-474 cells with 
E2 and HRG significantly increases colony size.  A) BT-474 cells were subjected to 
either siNT or siLRIG, 24 hours before being seeded in 2% soft agar and treated with 
ligand.  After 10 days, cell colonies were counted.  Knockdown of LRIG1 increases the 
number of colonies in soft agar.  Treatment with either E2 or HRG also increases the 
number of colonies compared to vehicle, with a further significant increase upon LRIG 
knockdown. Knockdown of LRIG and treatment of both E2 and HRG also results in an 
increase of colonies, though not more than that of either E2 or HRG alone. B) 
Representative images of BT-474 colonies following LRIG1 knockdown and treatment 
with vehicle, E2, HRG or E2/HRG in soft agar assay. C) LRIG knockdown increases 
the number of large colonies. Colony size was quantified using ImageJ software for 
controls (gray lines) and LRIG knockdown and treatment with vehicle, E2, HRG or a 
combination of E2 and HRG. 
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Figure 3.8. Treatment of MCF-7 cells with both E2 and HRG increases the 
number of large colonies.  A) Knockdown of LRIG1 increases the number of colonies 
in soft agar.  Treatment with either E2 or HRG also increases the number of colonies 
compared to vehicle, with a further significant increase upon LRIG knockdown. 
Knockdown of LRIG along with treatment of both E2 and HRG together also results in 
an increase of colonies, though not beyond that of either E2 or HRG alone.  B) LRIG 
knockdown increases the number of large colonies. Colony size was quantified using 
ImageJ software for controls (gray lines) and LRIG Knockdown cells treated with 
vehicle, E2, HRG or a combination of E2 and HRG. C) Representative images of BT-
474 cells following control (non-targeting) knockdown or LRIG1 knockdown and 
treatment with vehicle, E2, HRG or E2/HRG in soft agar assay. 
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Figure 3.9. LRIG1 levels in primary breast tumors.  A) LRIG1 mRNA expression 
in 238 primary  luminal A and luminal B tumors. LRIG1 mRNA expression in 68 
primary breast tumors after Tamoxifen treatment.  B)  Array Comparative Genomic 
Hybridization of 172 primary breast tumors. C)  LRIG1 mRNA expression in patients 
with or without metastatic recurrence.  (Data from www.oncomine.org/) 
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